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ABSTRACT 
 
Rachael Marie Liesman: Impact of the Non-structural 2 Protein on  
Respiratory Syncytial Virus Pathogenesis 
(Under the direction of Raymond Pickles) 
 
 
Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in 
young children. The factors contributing to increased propensity of RSV-induced distal 
airway disease compared to other commonly encountered respiratory viruses are unknown. 
Using a model of the well-differentiated airway epithelium, we characterized the 
consequences of RSV infection of ciliated epithelial cells, the primary cellular targets of RSV 
infection in vivo. These studies show that RSV infection results in cell rounding and 
degradation of the cilia apparatus, followed by active extrusion of infected cells from the 
epithelium, eventually resulting in a decline in the ability of the airway epithelium to perform 
mucociliary transport. Using recombinant respiratory viruses, we attribute these 
consequences to the RSV non-structural 2 (NS2) protein. Using parainfluenza virus 3 (PIV3) 
to deliver and express RSV NS2 in the ciliated epithelium of hamster airways, we assessed 
the impact of NS2 on respiratory viral pathogenesis. These studies identified the RSV NS2 
protein as a unique viral genetic determinant for RSV-induced pathogenesis, resulting in two 
distinct effects in vivo. First, NS2 promoted epithelial cell extrusion and accelerated 
clearance of whole lung virus titers, presumably by clearing virus-infected cells from the 
airway mucosa. Second, epithelial cell extrusion promoted by NS2 resulted in accumulation 
of detached, pleomorphic epithelial cells in the narrow diameter bronchiolar airway lumen, 
resulting in acute distal airway obstruction. Finally, we identify a role for NS2 in mediating 
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early and robust neutrophilic influx, which may contribute to distal airway obstruction and 
constriction. These studies reveal a novel consequence of RSV infection of the airway 
epithelium, where NS2-promoted epithelial cell shedding and morphologic changes 
accelerate viral clearance but also cause acute distal airway obstruction. NS2-promoted 
epithelial cell shedding in the distal airways and the resulting obstruction of these airways 
represent a mechanism that may explain why RSV is the dominant virus causing 
bronchiolitis in young children. We identify for the first time NS2 as a pathogenesis factor for 
increasing the likelihood for small airway obstruction during RSV infection. 
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CHAPTER I 
INTRODUCTION 
 
Epidemiology and Disease Burden 
Human respiratory syncytial virus is the most important etiological agent of 
respiratory disease in children worldwide and by age 2, over 95% of individuals have 
experienced at least one RSV infection (1, 2). Seasonal infections of RSV generally begin in 
autumn and, in the US, range in duration from 13 – 23 weeks (3). Infection of adults and 
children most frequently results in upper respiratory tract illness (URTI) causing common 
cold-like symptoms, which may progress to lower repiratory tract illness (LRTI).  
It has recently been estimated that 34 million new cases of RSV-associated lower 
airway disease occur globally in children less than 5 years of age, resulting in 66,000 – 
199,000 deaths per year (4). The majority of these deaths occur in underdeveloped 
countries with limited access to standardized healthcare. Each year in the United States, an 
estimated 1.5 million outpatient visits are attributable to RSV infections in children <5 years 
old, resulting in 75,000-125,000 hospitalizations, of which 1.5% require admission to the 
pediatric intensive care unit (5-7). Average length of hospital stay for infants diagnosed with 
RSV bronchiolitis is 3.5 days (8-10) and hospitalization due to RSV-associated bronchiolitis 
results in total estimated costs of up to 700 million US dollars annually (11). RSV infections 
clearly represent a significant economic and health burden both globally and in the United 
States. 
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Clinical Features of RSV Infection 
RSV infection results in a range of symptoms, varying from upper respiratory tract 
illness characterized by rhinorrhea to severe lower respiratory tract illness characterized by 
labored breathing necessitating oxygen supplementation. Although RSV infection often 
causes only URTI, 1 to 2% of infected individuals progress to severe lower respiratory tract 
infection, which can result in hospitalization with bronchiolitis being the most common 
clinical diagnosis (5, 12). RSV-associated bronchiolitis is known to be more severe and 
results in prolonged hospitalization compared to non-RSV associated bronchiolitis, resulting 
in a mortality rate of 0.01 – 0.5% annually (6, 9, 10, 13, 14). Studies of young children found 
that RSV infection results in twice as many visits to the emergency department, six times as 
many hospitalizations, and nine times as many deaths compared to seasonal influenza 
infections (15, 16). The most important risk factor for the development of RSV bronchiolitis is 
very young age (< 6 months).  Other risk factors include congenital heart defects, 
immunodeficiency, neurodevelopmental deficits, familial history of atopy, chronic lung 
disease, and bronchopulmonary dysplasia (7, 9, 17, 18). Low body weight at time of 
hospitalization is most significantly associated with all measures of severe disease, with 
premature infants being the largest at-risk population (19). Despite identification of 
numerous factors associated with elevated rates of hospitalization, ~50% of RSV-associated 
hospitalizations occur in healthy children born at term with no additional identifiable risk 
factors (17). 
Natural infection by RSV does not induce lifelong immunity to reinfection and 
recurring infections are common despite no significant antigenic change of the virus (1). 
RSV infection among the elderly and immunocompromised populations is recognized as a 
significant health problem. In community-dwelling US adults over age 65, RSV is the 
etiological agent in 3-15% of incidences of acute respiratory illness per year (20-23). Among 
elderly patients admitted to the hospital with acute cardiopulmonary disease, 7 – 10% were 
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identified as RSV-induced illness and, in one study, 18% of RSV-infected patients were 
admitted to the intensive care unit (24, 25). RSV associated mortality rates are higher in the 
elderly population than among young children (16). Additionally, RSV causes increased 
morbidity and mortality in immunocompromised patients, particularly in transplant patients 
(especially lung and bone marrow transplants) and patients with leukemia. In nosocomial 
outbreaks among bone marrow transplant patients, RSV has been detected in 2 – 20% of 
patients, resulting in a pneumonia-associated mortality rate of 55 – 80% (26-28). Aggressive 
treatment using aerosolized ribavirin and intravenous immunoglobulin (IVIG) is frequently 
initiated at the onset of upper respiratory tract illness, although this treatment regime is 
costly and cumbersome (29, 30). Recently, clinical efficacy and tolerance of oral ribavirin 
has demonstrated, representing a promising, cost-effective therapeutic strategy for RSV 
infection in immunocompromisd patients (31, 32). 
 Although the majority of infants infected by RSV eventually resolve infection and 
disease, history of RSV infection can be associated with long-term abnormalities in 
pulmonary function, including asthma, airway hypersensitivity, and recurrent wheezing (33-
35). It is well accepted that severe LRTI is associated with an increased risk of wheezing, 
though a causal relationship to RSV infection remains controversial. An RSV-neutralizing 
antibody treatment (Palivizumab) used as prophylaxis for RSV infection also reduces 
recurrent wheeze in preterm infants, implicating RSV infection as an important cause of 
post-bronchiolitis wheeze (36, 37). Risk factors for development of wheeze following RSV 
infection include severity of disease as well as allergic risk factors, such as familial history of 
atopy or asthma, and predisposition to airway hypersensitivity (33, 35, 38-40). The 
association of severe RSV disease to long-term airway morbidity further highlights the need 
for effective treatment strategies to reduce the severity of clinical disease. 
4 
 
Treatment Strategies and Vaccine Development 
Despite the significant impact of RSV bronchiolitis on infant health, therapeutic 
treatment options to reduce the severity of distal airway disease are limited to poorly 
efficacious anti-viral and anti-inflammatory therapies, supplemental oxygen, or mechanical 
ventilation. There remains a significant clinical need to reduce the severity of RSV-induced 
distal airway disease in infants and young children as well as elderly and 
immunocompromised populations. 
Treatment with the RSV-neutralizing monoclonal antibodies palivizumab or 
motavizumab caused a slight reduction in viral shedding, yet no clear clinical benefit has 
been demonstrated (41-43). Prophylactic use of these antibodies, however, has shown to 
significantly reduce the severity of disease, although treatment as prophylaxis relies on 
expensive monthly injections and is therefore restricted to at-risk populations (14, 44-48).  
Ribavirin is the only anti-viral drug currently approved for treatment of RSV infection. 
Although exhibiting anti-viral efficacy in tissue culture models and experimentally infected 
animals (49), studies of clinical use of ribavirin in RSV-infected infants and young children 
have failed to show significant reduction in disease outcome (50-53).  Due to efficacy 
concerns, difficulty of delivery (aerosol), and potential side-effects in neonates, ribavirin is 
not currently used for routine clinical treatment of RSV in infants and young children (54). 
Clinical efficacy, however, has been shown for treatment of RSV infection in 
immunocompromised patients and nebulized, oral, or intravenous ribavirin treatment 
remains widely used, despite concerns for tolerance and safety (31, 32, 55). 
 In the absence of efficacious anti-viral therapies, bronchodilators and anti-
inflammatory steroids remain widely used to dampen the inflammatory consequences of 
RSV bronchiolitis despite sufficient evidence these treatments provide no clinical benefit. 
Meta-analysis of corticosteroid use in hospitalized non-intubated patients demonstrated only 
at 0.5-day decrease in duration of hospital stay with steroid use (56). Steroids have also 
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shown no clinical effect on hospital admission rates, concentration of proinflammatory 
cytokines in tracheal aspirates, or length of mechanical ventilation (57-59). A more 
comprehensive, multi-center placebo controlled trial demonstrated no effect of 
dexamethasone on clinical outcome of disease (60). In spite of these studies, corticosteroid 
treatment for RSV infection is still used in conjunction with bronchodilators.  
Despite decades of study and an obvious need, licensed RSV vaccines are currently 
unavailable. Because of the early age of first RSV infection, vaccination should occur within 
the first weeks of life. The likely need for multiple doses at such an early age further 
complicates the development of a pediatric RSV vaccine. In the 1960s, a formalin-
inactivated RSV vaccine (FI-RSV) was developed and evaluated. Though immunogenic, this 
vaccine demonstrated poor protection against natural RSV infection and vaccinated 
individuals experienced immune-mediated enhancement of disease resulting in 
hospitalization of nearly 80% of infected vaccinated individuals, including two fatalities (61). 
The failure of this vaccine has been attributed to an aberrant immune response to FI-RSV 
that did not result in the production of neutralizing antibodies and induced an immune 
response inherently different to that induced by a natural RSV infection (61-63). As a result, 
inactivated whole-virus vaccine development has largely been abandoned and current 
vaccine development strategies are focused on live-attenuated vaccines, subunit vaccines, 
and virus-like particle vaccines.  Biologically-derived RSV vaccines, such as vaccines based 
on cold-passaged viruses and temperature sensitive mutants, have been evaluated clinically 
but discontinued due to insufficient attenuation in infants (64). Live-attenuated vaccines 
were revisited with the introduction of RSV reverse genetics technology, and novel 
combinatorial mutations in several different RSV genes have yielded promising vaccine 
candidates currently in pre-clinical and clinical trials (65-69). 
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RSV Virology 
RSV is classified within the family Paramyxoviridae, subfamily Pneumovirinae, and 
has a negative-sense, single-stranded RNA genome with 10 genes encoding 11 proteins.  
RSV encodes for 3 transmembrane glycoproteins: the fusion protein F, the attachment 
protein G, and the small hydrophobic protein SH. The matrix M protein is essential for the 
structure and assembly of the virion. The RNA genome associates with 4 proteins within the 
virion: the nucleoprotein N, the phosphoprotein P, the transcription processivity factor M2-1, 
and the large polymerase protein L. M2-2 is encoded by a small ORF within the M2 mRNA 
and may play a role in RNA synthesis. Two non-structural proteins, NS1 and NS2, are 
encoded by the virus and are not packaged within the virus particle. Replication occurs in 
the cytoplasm and the RNA genome is transcribed sequentially to produce 10 separate 5’ 
capped mRNAs. Each individual gene begins with a highly conserved gene start signal that 
initiates mRNA synthesis and ends with a semi-conserved gene end signal that directs 
termination and polyadenylation of the mRNA. Dissociation of the viral polymerase after the 
gene end signal results in a gradient of transcription, whereby genes proximal to the 3’ 
region are transcribed first and at a greater abundance than genes more distal to the leader 
sequence. RSV assembly and budding occur at the plasma membrane resulting in spread of 
infection.  
 
Attachment and Entry: G Glycoprotein 
 The RSV glycoprotein (G) and fusion protein (F) mediate attachment and entry of 
RSV to the target cell. RSV binding and entry is a two-step process, whereby the virion first 
attaches to the cell membrane followed by a fusion event. In cell line models of infection, the 
F protein is sufficient for binding and entry of RSV and, although the G protein enhances 
attachment and syncytia formation, G is not considered required for entry (70-73). 
Attachment and entry of RSV likely involves interactions between cellular proteins and the 
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RSV F and G protein. A specific cellular receptor for RSV has yet to be identified, though the 
discovery of interactions between the cell surface nucleolin protein and RSV F suggest 
promising avenues of research (74, 75). G-mediated attachment to cultured cells is 
dependent on glycosaminoglycans (GAGs) on the cell surface (76, 77). GAGs are repeating 
disaccharide units of hexuronic acid and hexosamine that form unbranched polysaccharide 
chains. Heparan sulfate (HS) is the GAG most commonly associated RSV entry into HEp2 
cells, and G-mediated attachment likely involves electrostatic interaction between G and HS, 
though requirements for GAG structural elements have been noted (76-79). Although 
interactions between G and HS have been well documented, HS is not detectable on the 
surface of primary well-differentiated models of the human airway epithelium (80, 81). 
Several other GAGs have been detected on the surface of the airway epithelium, including 
keratan sulfate, chondroitin / dermatan sulfate, and hyaluronan (82), though it is unclear 
what the role of GAGs are for attachment of RSV to target cells in the human airway 
epithelium. 
A small hydrophobic region near the N-terminus of the G protein serves as a 
membrane anchor, resulting in insertion of G into the cell membrane and incorporation into 
the viral envelope. G is an extensively glycosylated protein, with the external component of 
the protein containing 4 predicted N-linked glycosylation sites and 24-25 predicted O-linked 
glycosylation sites (83). N-linked carbohydrate groups are added first in the ER, increasing 
to size of G from 32 kDa to an apparent 45 kDa processing intermediate form, which are 
then converted to complex sugars in the trans-Golgi network. O-linked oligosaccharides are 
also added in the Golgi compartment and O-linked sugars are estimated to comprise ~50% 
of the total mature 90 kDa form of G (84, 85). The glycosylation profile is cell-type specific, 
as G produced in different cells lines exhibits different electrophoretic mobility (86, 87). Due 
to heavy glycosylation and a lack of secondary structure, the ectodomain is referred to as 
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having a “mucin-like” structure, which may help shield the virion from antibody recognition 
(84).  
Translation from a second initiation site within the G open reading frame results in a 
truncated G that is further cleaved to completely lack the membrane anchor, and this 
truncated protein is secreted (88, 89). Secreted G (sG) is rapidly secreted in cell culture, 
comprising 80% of total G protein released within 24h post inoculation (88). While the 
contributions of sG in productive infection remains to be fully elucidated, evidence indicates 
a role for immune evasion and antibody decoy (90, 91).  
 
Immune Evasion Strategies: NS Proteins 
RSV encodes 2 non-structural proteins, NS1 and NS2, at the 3’ beginning of the 
genome immediately following the leader sequence. These genes are expressed to high 
levels immediately upon infection, with both proteins being detectable 5h post-infection of 
A549 cells (92). NS1 and NS2 have primary roles as type I and III interferon (IFN) 
antagonists and deletion of one or both of these genes from recombinant RSV resulted in a 
large increase in type I IFN expression and signaling in infected human epithelial cell 
cultures and macrophages (93, 94). The magnitude of increase was greater following 
deletion of the NS1 gene as compared to deletion of NS2, though deletion of both genes 
produced the greatest effect (93). Co-immunoprecipitation studies indicate these proteins 
form a heterodimer, although expression of both proteins together does not appear to be 
essential to function (95).  The mechanisms by which these proteins inhibit type-I interferon 
are complex, involving both coordinated and independent functions.  
The signal transduction pathways involving IRF3 activation are significant targets for 
antagonism by both NS1 and NS2. IRF3 is a major interferon regulatory factor which, upon 
activation, dimerizers and transports to the nucleus to activate transcription at IFN-response 
elements (ISREs). Activation of IRF3 can occur downstream of Toll-like receptor (TLR) and 
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RIG-I-like receptor (RLR) activation, including TLR3 and RIG-I which are known to activate 
upon RSV infection (96, 97). NS2 has been shown to bind RIG-I, preventing interactions 
between RIG-I and MAVS to block signal transduction and prevent activation of IRF3 (98). 
Additionally, expression of either NS1 or NS2 resulted in a decrease in TRAF3 protein 
levels, which is downstream of MAVS along the signal transduction pathway leading to IRF3 
activation (95). In the same study, NS1, but not NS2, was shown to decrease activation of 
IKKε, a protein kinase involved in activation of IRF3 (95). 
Type I IFN-mediated signal transduction is also strongly suppressed by RSV through 
the JAK/STAT pathway. Both NS1 and NS2 have been shown to decrease protein levels of 
STAT2 (99, 100), likely via the proteosomal degradation pathway. Indeed, NS1 can function 
as an E3 ligase due to the presence of an elongin C and cullin 2 binding domain, resulting in 
ubiquitination and degradation of STAT2, and mutation of this domain results in degradation 
of the NS1 protein and attenuation of the virus (101, 102). Additional studies, however, 
indicate a primary role of NS2 in degradation of STAT2, where expression of both NS1 and 
NS2 together enhanced STAT2 degradation over NS2 expression alone, though expression 
of NS1 had no effect on STAT2 degradation (95, 99, 100). 
RSV also inhibits activation of the type III IFN pathway in human epithelial cells and 
macrophages (93). The observed effects of NS1 and NS2 on type III IFN induction were 
similar to those demonstrated for type I IFN induction (93). The induction of the type I and III 
pathways occurs through different receptors, though both receptors signal through the 
JAK/STAT pathway and utilize STAT2 (103), which may account for similar effects of NS1 
and NS2 on type I and III IFN induction. Type III IFN receptors are expressed primarily in 
epithelial cell types, suggesting a potentially important role for immune regulation in 
pulmonary epithelial cells (103). 
Pro-survival roles via activation of NF-kB by the NS proteins have also been 
demonstrated in cell lines. Deletion of NS1 or NS2 reduced RSV-mediated activation of NF-
10 
 
kB (104). Knockdown of NS1 or NS2 using siRNA also resulted in a reduction in several 
anti-apoptotic functions, including activated forms of NF-kB and phosphorylation of AKT, 
leading to early apoptosis (92). Suppression of apoptosis by the NS proteins also occurs in 
Vero cells which lack IFN-α and –β genes, suggesting anti-apoptotic functions of the NS 
proteins may be IFN independent (92).  
Predictably, deletion of the NS1 or NS2 genes from a recombinant RSV results in 
reduced titer in cultured interferon-competent cell lines (93). In seronegative chimpanzees, 
NS1 and NS2 deletion mutants are highly attenuated (105-107), further emphasizing the 
role of NS1 and NS2 in RSV replication and pathogenesis. 
 
Human Airway Epithelia 
The human respiratory epithelium is the primary target of RSV infection. The 
conducting airways extend from the nose to the terminal and respiratory bronchioles and 
serve as a protective physical barrier between the external environment and host tissues as 
well as controlling the temperature and humidity of inspired air. The alveolar regions occupy 
the greatest internal surface area of the lung and facilitate gas exchange. 
The cartilaginous conducting airways are lined by a pseudostratified ciliated 
epithelium consisting of basal, ciliated, and secretory cell types. The columnar cell 
superficial epithelium attaches to a sublayer of cuboidal basal epithelial cells, which serve as 
an attachment point to the basement membrane and function as progenitor cells (108, 109). 
Ciliated cells are the predominant columnar cell-types throughout the conducting airways 
(110). Goblet cells can extend into but not distal to the bronchiolar regions and secrete 
mucus into the airway essential for mucociliary clearance. Club (Clara) columnar cells are 
located predominately in the distal airways in humans, although regional distribution of this 
cell type is species dependent (111, 112). Club cells play important roles in detoxifying 
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noxious inhalants and maintaining distal airway defense by secreting proteases, anti-
microbial peptides, surfactants, anti-proteases, and anti-inflammatory proteins (113).  
In vitro models of well-differentiated airway epithelia indicate that RSV primarily 
infects columnar ciliated cells while sparing goblet and basal cells (114, 115). RSV infection 
of ciliated epithelial cells, but not basal cells, was noted throughout the respiratory tract of 
RSV-infected individuals post-autopsy and in calves experimentally infected with bovine 
RSV (116, 117). In the smaller, non-cartilaginous airways, RSV infection was also noted in 
non-ciliated columnar and cuboidal cells. In the larger airways, infection was evident in non-
contiguous clumps of epithelium, while circumferential airway infection was often noted in 
smaller airways (117). Infection did not cause overt cytopathogenesis, as intact RSV-
positive epithelial layers are found in vivo and airway epithelial models note no obvious 
deterioration of the epithelium (115, 117-119). In polarized models of epithelial cells, RSV 
sheds from the apical surface of infected cells into the apical lumenal space with no 
infectious virus detectable in the basolateral compartment (8, 114, 115).  
Due to constant contact with the external environment, including insults from 
environmental toxicants, allergens, and pathogens, the respiratory mucosa employs a 
multitude of innate defense mechanisms, both physical and biological, to preserve the 
integrity of the epithelium and ensure efficient gas exchange. Epithelial cells play a critical 
role in regulating the immunological homeostasis of the airway. These cell types are also 
are common targets of respiratory viruses and these viruses have evolved diverse 
mechanisms to subvert the inter- and extracellular levels of innate airway defense. Our 
current knowledge of innate airway defense mechanisms and the methods by which RSV 
subverts these to establish respiratory infection are summarized in the following section. 
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Airway Defense Mechanisms: Protective Barrier 
 The columnar airway epithelium, existing at the interface of the external environment 
and the internal milieu, serves a critical role in airway defense by providing a physical barrier 
to systemic penetration of pathogens crucial to maintaining lung sterility. Barrier integrity is 
established and maintained by tight junction proteins, the most apically located of the 
epithelial junction complexes. Occludin, claudin, and junctional adhesion molecule (JAM) 
proteins form tight junctions, in addition to the family of scaffold PDZ-domain expression 
proteins, including zonula occludens (ZO)-1 (120). Tight junctions primarily serve to inhibit 
water and solute flow through intercellular spaces between cells and to establish the polarity 
of columnar epithelial cells (121-123). 
Studies of the effects of RSV infection on membrane barrier integrity have largely 
concluded that RSV does not have a gross cytopathic impact on barrier integrity of the 
epithelial membrane. Infection of well-differentiated models of the columnar airway 
demonstrate no changes in staining intensity or location of ZO-1, a protein integral to tight 
junctions of airway epithelial cells (114). Measurements of transepithelial electrical 
resistance (TEER), an index of tight junction and barrier integrity, in well-differentiated 
cultures infected with RSV show only modest decreases in TEER compared to control, 
indicating no significant compromise of barrier integrity (124, 125).  
 
Airway Defense Mechanisms: Epithelial Cell Response 
 The ciliated cell is the site of first contact with invading pathogens and acts as both a 
target and an effector cell to mediate the cellular response to viral infection. This response 
includes production of anti-viral and pro-inflammatory cytokines but may lead to the initiation 
of apoptosis and eventual extrusion of the infected cell from the epithelium into the airway 
lumen. 
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 Interferon: Interferon (IFN) production and release is an integral component to the 
cellular antiviral response. Three classes of IFN have been described and are designated 
type I, type II, and type III. Type I inteferons include IFN-α, IFN-β, and IFN-ω and are the 
major class of IFN expressed in mammalian cells. Type II IFN, or IFN-γ, is produced by 
natural killer cells and activated T cells. Type III interferons include the IFN-λ family and 
signal via downstream pathways similar to the type I IFN signal transduction pathway, 
though the type III IFN receptor is restricted to epithelial cell types (103). Ciliated columnar 
cells signal through both the type I and type III IFN, though the type I IFN signal transduction 
pathway is thought to be more important. Secretion of type I IFN from virally infected cells 
acts in both autocrine and paracrine fashion by binding the type I IFN receptor at the cell 
surface and stimulating signaling through the JAK/STAT pathway, whereby STAT signaling 
complexes translocate to the nucleus to initiate transcription at numerous IFN-stimulated 
response elements (ISREs). The RSV NS proteins subvert type I IFN signaling via 
interactions with the JAK/STAT arm of the signaling pathway and IFN-α/β secretion is 
significantly reduced or absent in infants and adults infected with RSV (93, 95, 99, 100, 126-
128). Interestingly, a recent study identified type III IFN as the predominant IFN secreted in 
nasal epithelial cells infected with RSV and demonstrated suppression of viral replication in 
the presence of IFN-λ (129). 
 Cytokines: Virally infected epithelial cells also release a diverse array of cytokines 
and chemokines that function as both pro- and anti-inflammatory mediators to modulate the 
pulmonary immune response. Production of cytokines following RSV infection has been 
characterized in epithelial cell lines and well-differentiated models of the airway epithelium, 
as well as in vivo in nasal aspirates, bronchoalveolar lavages, and blood from RSV-infected 
infants.  
 IL-1β, IL-6, and TNF-α release mediate a wide range of proinflammatory processes 
and are implicated in the immunoregulation of RSV disease. IL-1β is secreted from RSV 
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infected epithelial cells and well-differentiated models of RSV infection (130, 131) and is 
detectable in infants experiencing RSV bronchiolitis (118, 132). Elevated IL-1β levels in 
nasopharyngeal secretions have been directly associated with severity of RSV disease 
(133). TNF-α is increased in tissue culture models of infection as well as infants with RSV-
induced bronchiolitis (104, 118, 132, 134-136). IL-6 is also detected in cell lines and airway 
epithelium models infected with RSV (114, 124, 131, 137) and in nasophyngeal secretions 
and bronchoalveolar lavage fluid from RSV-infected infants (118, 132, 134-136, 138). 
 Cytokine secretion is an important mechanism for recruitment of immune effector 
cells to sites of infection. IL-8 and CXCL10 are a major chemoattactants for neutrophils and 
are produced by both epithelial cells and macrophages in response to RSV infection (104, 
114, 124, 131, 137, 139, 140). IL-8 levels are elevated in serum, nasophyngeal secretions, 
and bronchoalveolar lavage samples from infants with severe RSV bronchiolitis (118, 132, 
138, 141-143). Elevated IL-8 levels in nasophyngeal aspirates are also associated with RSV 
disease severity (144). RANTES is a major chemoattractant for eosinophils and expression 
is upregulated following RSV infection of cell lines (104, 145) and airway models of infection 
(114, 124, 131, 140), and is detectable in RSV-infected infants (138, 143, 146). 
 The list of cytokines reviewed in this section is not exhaustive and many other 
cytokines have been detected in studies of RSV infection of cell lines, airway models, animal 
models, and humans. Emphasis was placed on cytokines secreted from airway epithelial 
cells, cytokines associated with leukocyte recruitment at early times after infection, and 
cytokines associated in increased severity of RSV disease.  
Club cell secretory proteins: In human airways, club (Clara) cells are located in the 
terminal-respiratory bronchiolar regions and are the major type of non-ciliated secretory cells 
in the bronchial region, comprising10 – 25% of cells in the human epithelia (113, 147, 148). 
RSV-positive club cells have been observed in the distal airways of calves, lambs, and 
infants infected with RSV, suggesting that RSV can target this cell type for infection and 
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replication (116, 117, 149). Club cells participate in the innate defense of the airway by 
secreting several anti-inflammatory proteins, including CC10 (also known as CCSP, 
secretoglobin, and uteroglobin), surfactant protein A (SP-A), and surfactant protein-D (SP-
D). Damage to club cells is associated with exacerbated lung injury and inflammation after 
exposure to irritants (150). Few studies have investigated the role of club cells in the context 
of RSV infection. CC10- and SP-D-deficient mice, when challenged with RSV, show 
increased viral persistence and lung inflammation (151, 152). SP-A and SP-D gene 
expression was increased in RSV-infected neonatal lambs, suggesting an important role for 
club cells during RSV infection (153).  
 Apoptosis and cell extrusion: Though infected epithelial cells initiate numerous 
anti-viral and pro-inflammatory signaling cascades, cell death can be the final outcome of 
viral infection. Cell shedding induces anoikis, a process defined as induction of apoptosis by 
disruption of cell-cell interactions (154, 155). Induction of anoikis serves to limit both viral 
replication and cytokine release, ridding the epithelium of cytokine-producing infected cells 
to dampen pro-inflammatory signals (156, 157). Furthermore, regulation of cell death and 
shedding helps to preserve the integrity of the epithelial barrier and reduce damage caused 
by infiltrating immune cells (158). Shed cells are then available for clearance from the airway 
lumen by mucociliary clearance mechanisms.  
 Anoikis and cell shedding are likely consequences of RSV infection of the airway 
epithelium. Increased numbers of cells are detected in the apical compartment of RSV 
infection of well-differentiated airway epithelial cell cultures, suggesting that infected cells 
are sloughed from the epithelium (114, 124, 125). Sloughed, antigen positive cells have 
been noted in the airway lumen of experimentally infected animals and, in addition to 
inflammatory debris, these cells contribute to airway obstruction and narrowing of the airway 
lumen, suggesting a potential role for cell shedding in RSV pathogenesis (116, 153, 159, 
160).  Histological examination of tissue sections from infants infected with RSV have also 
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documented RSV-antigen positive epithelial cells within the airway lumen (117, 118, 161). 
Despite the frequent appearance of RSV-infected cells in the airway lumen, the process of 
airway epithelial cell death and shedding following RSV infection has yet to be fully 
characterized and the importance of this process in development or limitation of RSV-
associated disease is unknown. 
 
Airway Defense Mechanisms: Mechanical Clearance 
Several types of mechanisms mediate clearance of airway debris following viral 
infection, including immune-cell mediated and mechanical clearance, and these 
mechanisms work in tandem to facilitate clearance of viral infection and resolution of 
disease. In immune-cell mediated clearance, macrophages, dendritic cells, T cells and 
neutrophils migrate to the airway parenchyma to kill and clear infected cells via 
phagocytosis. Mechanical clearance includes both mucociliary clearance and cough 
clearance mechanisms. Cough clearance, including cough and sneeze, occurs when 
sensory nerves imbedded in the tracheobronchial region are stimulated, either by 
mechanical or inflammatory stimulation (162, 163). During periods of viral replication and 
shedding, coughing or sneezing likely aids the dissemination of viral particles to subsequent 
hosts.  
Pathogens that settle on the airway surface encounter a complex mesh of mucins, 
decorated with a diverse library of carbohydrate side chains that are able to interact non-
specifically with particles within the respiratory tract. Mechanical clearance of mucus serves 
to clear material trapped in the mucus gel via mucociliary transport. Mucociliary clearance is 
dependent upon tight regulation of the viscoelastic properties of the mucin layer and rapid, 
unidirectional, coordinated cilia beat, resulting in an “escalator” function to clear particles 
deposited in the mucus layer from the small airways to the proximal airways and larynx 
(164-167). Disruption of either of these clearance mechanisms has profound impact on the 
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ability of the host to clear respiratory pathogens. Maintenance of a hydrated airway surface 
is crucial to the function of cilia and individuals with diseases characterized by depletion in 
airway surface liquid volume, such as cystic fibrosis (CF), suffer impaired cilia beat. The 
dehydrated and static mucus layer may then adhere to the epithelial cell surface, resulting in 
impaired mucociliary clearance and contributing to increased bacterial infections and airway 
obstruction (168-170). Individuals primary ciliary dyskinesia (PCD), characterized by defects 
in cilia beat and coordination, experience increased respiratory tract infection and sinusitis 
resulting from a significant reduction in cilia dependent mucus clearance (171, 172). Cough 
clearance remains normal in these patients, possibly accounting for the less severe disease 
pathogenesis of PCD compared to CF (173).  
Pathogenic effects of RSV infection on cilia structure and function have been noted 
in well-differentiated models of the human airway epithelium, animal models of infection, and 
infants naturally infected with RSV. RSV infection of airway models results in an overall 
decrease of cilia, as determined by β-tubulin staining, and increase in ciliary dyskinesia 
(114, 174, 175). RSV-infected ciliated cells demonstrate abnormal beat pattern as early as 
24 hours pi and uninfected cells show no changes in cilia structure or function, suggesting 
that cilia degradation is a direct effect of RSV infection, rather than resulting from release of 
a soluble factor (175). Studies of calves infected with bovine RSV noted disruption of the 
cilia apparatus, where infected ciliated cells have fewer intact cilia than uninfected cells, 
basal bodies are disorganized within infected ciliated cells, and ciliary fragments are present 
in the airway lumen (116). Nasal biopsies from infants with RSV-associated bronchiolitis 
showed decreased numbers of ciliated cells within the epithelium, increased numbers of 
cells detached from the epithelium, and abnormalities in ultrastructural features of cilia as 
compared to uninfected controls (176). 
Disruptions in cilia function may impair mucociliary clearance of shed cells and 
debris in the airways, potentially leading to acute airway obstruction. Air-trapping and 
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reduced pulmonary function are characteristic of acute obstructive disease and are 
associated with severe RSV disease in both infants and animals models (5, 177). Effective 
mechanical clearance mechanisms are important for clearance of shed cells and debris in 
the distal airways of infants or animals experiencing RSV infection. Impairment of 
mucociliary clearance may contribute to the distal airway obstruction noted in experimental 
models of RSV disease, which likely contributes to early pulmonary function changes 
following RSV infection. Although the clinical implications of RSV-mediated disruptions in 
mucociliary clearance are not yet defined, the inability to clear infection may be associated 
with more severe disease. In otherwise healthy infants with naturally occurring RSV 
infection, inability to clear RSV, as measured by higher viral loads in nasal washes at later 
timepoints, was associated with prolonged hospitalization, increased disease severity, and 
increased risk of requiring intensive care in RSV infected infants (19). In experimentally 
infected adults, viral load correlated with symptom severity, intranasal cytokine secretion, 
and nasal mucus output, further highlighting the importance of viral clearance on disease 
outcome (178).  
 
Airway Defense Mechanisms: Cellular Immune Response 
In addition to mediating infection through both biological and physical mechanisms, 
the columnar airway epithelium plays a major role in recruitment of inflammatory cells that 
contribute to the antiviral response of the airway. Neutrophils are the most common 
leukocyte associated with RSV bronchiolitis and, in RSV infected infants, neutrophils 
represent 80 – 93% of cells in upper airway aspirates (nasalphyrangeal aspirates) and 76 – 
83% of cells in lower airway lavage fluid (bronchial lavage) (179-182). Neutrophilic infiltrates 
have also been noted in animal models of RSV infection. Histological examination of calves 
infected with bovine RSV demonstrated neutrophils associated and occasionally fused with 
infected epithelial cells (116). The recently developed neonatal lamb model for RSV 
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infection has also demonstrated neutrophil influx into the airway lumen following infection 
with RSV, with neutrophils located below the basement membrane as well as within the 
infected airway lumen (153, 183, 184). IL-8, the major chemoattractant of neutrophils, is 
released by airway epithelial cells in vitro and is detectable in prenatal lambs and infants 
infected with RSV (143, 184-187). 
To arrive in the airway lumen, neutrophils leave systemic circulation and must 
migrate across the respiratory mucosa (188, 189). Adherence to the epithelium is mediated 
by interaction between CD11b/CD18 on the surface of neutrophils with ICAM-1 on the apical 
surface of epithelial cells and is important in neutrophil mediated cytotoxicity and 
phagocytosis (190, 191). Upregulation of ICAM-1 has been noted in epithelial cells infected 
with RSV and increased neutrophil adherence has been demonstrated on epithelial cell 
monolayers infected with RSV (191-194). Release of soluble mediators following neutrophil-
epithelial cell interactions, such as neutrophil elastase and matrix metalloproteinases, 
contribute to neutrophil mediated epithelial damage. Although neutrophils are present in 
large numbers following RSV infection, the impact of the dual functions of viral clearance 
and epithelial damage on development and severity of RSV-mediated disease is not yet 
completely understood.  
 
Dissertation Objectives 
Respiratory syncytial virus is the most frequent cause of bronchiolitis and severe 
lower respiratory tract illness in infants and children. Despite being first identified in 1955, 
treatment options to reduce severity of disease remain limited and no vaccine currently 
exists. Although epidemiologic risk factors of RSV disease have been well characterized, an 
understanding of the underlying mechanisms of severe disease remains elusive. 
Specifically, the role of the columnar airway epithelium in modulating RSV disease and the 
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underlying viral and epithelial processes responsible for initiation of bronchiolitis remain to 
be explored. 
Tissue culture cell line models have provided valuable information on RSV virology 
and pathogenesis, however, these cells are non-polarized and may not accurately reflect 
interaction of RSV with the polarized, pseudostratified airway epithelium, the host target of 
RSV infection. Rodent models of RSV infection, especially mice, show limited 
permissiveness to RSV lower airway infection and pathological and immunological changes 
can differ from clinical observations of RSV infected infants. Infection with closely related, 
species-specific pneumoviruses such as bovine RSV (bRSV) or ovine RSV (oRSV) has 
provided valuable information on pathology, but these studies are severely limited by 
expense, space, and ethical concerns.  Autopsy and biopsy studies of human RSV infection 
are often confounded by co-morbidity with additional respiratory illness (e.g. viral or bacterial 
coinfection or underlying genetic disease) and treatment (e.g. mechanical ventilation) that 
greatly impact histopathological findings of these studies. As a result, we currently have a 
poor understanding of the pathogenic mechanisms of lower respiratory tract infection that 
lead to severe disease outcomes. The use of a well-differentiated polarized airway model of 
RSV infection is integral to understanding the response of ciliated airway epithelial cells to 
RSV infection. Connecting mechanisms of epithelial cell pathogenesis to pathogenic 
findings of early RSV infection in an in vivo model will contribute to an understanding of the 
early features of RSV mediated disease.  
The purpose of this dissertation was to explore interactions between RSV infection 
and ciliated airway epithelia. The overarching goals of these studies were to understand the 
interaction of the RSV virion with the ciliated cell, determine the consequences of RSV 
infection of the ciliated cell, track the fate of ciliated cells following RSV infection, and 
explore the role of the NS2 protein in RSV infection of ciliated cells. To that end, we utilized 
recombinant RSV and PIV3 viruses and in vitro well-differentiated airway model and in vivo 
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hamster model of infection. We demonstrate the importance of ciliated cells in mediating 
RSV infection, as the ciliated cell upregulated pro-inflammatory and anti-viral modulators 
and participated in controlled extrusion from the airway epithelium to clear viral infection 
while maintaining the integrity of the epithelium. We identify a novel function of the NS2 
protein to cause morphological rounding of columnar epithelial cells upon infection with 
RSV. Using an in vivo model, we demonstrate two consequences of NS2 induced cell 
rounding and shedding. In the larger airways, NS2 enhances clearance of viral titer and 
infected cells from the airway. In the smaller airways, NS2-mediated cell rounding and 
shedding causes acute bronchiolar obstruction, which may play a role in initiation of 
bronchiolitis.  
 
 
 
  
 
CHAPTER II 
THE ROLE OF THE G GLYCOPROTEIN IN EFFICIENT RSV INFECTION 
 OF HUMAN CILIATED AIRWAY CELLS  
 
2.1 Overview 
The G glycoprotein on the surface of human respiratory syncytial virus serves as an 
attachment protein to enhance infectivity of RSV in cell line monolayers. Here, we 
demonstrate a requirement for the G protein for efficient RSV infection of a primary, well-
differentiated model of the human airway epithelium (HAE). We also describe differences in 
electrophoretic mobility of G produced in different cell lines, where virions grown in Vero 
cells primarily display a 55 kDa G protein, likely representing a processing intermediate, 
while virions grown in HEp2 cells display a 90 kDa protein. A novel, 180 kDa form of G is 
identified from virions grown in ciliated cells of HAE. Vero-cell grown virus infected HAE 600-
fold less efficiently than HEp2 grown virus, suggesting an important role G glycosylation and 
processing in infection of ciliated cells. Finally, we report on the generation of a HEp2 cell 
line that expresses a viral IFN antagonist and cannot respond to IFN. This HEp2-V cell line 
supports replication of attenuated viruses to high yields and practical applications of this 
reagent are discussed. 
 
 
 
__________________________ 
Sections of this chapter previously appeared in the Journal of Virology. Copyright © American Society 
for Microbiology, J Virol. 2009 Oct; 83(20): 10710-8. doi: 10.1128/JVI.00986-09 
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2.2 Introduction 
Human respiratory syncytial virus (RSV) is a negative-sense, single-stranded RNA 
virus in the family Paramyxoviridae, subfamily Pneumovirinae. RSV causes mild-to-
moderate upper respiratory disease, which can progress to severe or fatal lower respiratory 
tract disease primarily in infants and the elderly population. Currently no licensed vaccine is 
available and treatment generally consists of anti-viral and anti-inflammatory therapies with 
limited efficacy and supportive therapy. 
RSV expresses three glycoproteins on the virion surface. The large glycoprotein (G) 
plays a role in attachment (195), the fusion (F) glycoprotein mediates virion fusion to the 
target cell membrane (196), and the small hydrophobic (SH) glycoprotein may attenuate 
apoptosis (197). Of these glycoproteins, only the F protein is absolutely required for infection 
of cell-lines, although the G protein enhances infection and syncytia formation (77, 198). G 
functions by attaching to glycosaminoglycans (GAGs) on the surface of immortalized cells 
(76, 199, 200). GAGs are repeating disaccharide units of hexuronic acid and hexosamine 
that form unbranched polysaccharide chains and are expressed on the surface of most 
mammalian cells. Several types of GAGs have been characterized and heparan sulfate (HS) 
is the most important GAG for RSV infection of HEp2 cells (78, 79). 
The G protein is a type II integral membrane protein with a cytoplasmic N-terminus 
and an extracellular C-terminal ectodomain. A small hydrophobic region near the N-terminus 
serves as a membrane anchor. The ectodomain of G contains several predicted N- and O-
linked glycosylation sites. The unglycosylated protein is predicted to be 32 kDa in size and is 
modified by addition of N-linked sugars while in the endoplasmic reticulum, increasing the 
predicted size of G to 45 – 60 kDa (84). G proteins of this size are likely partially 
glycosylated processing intermediates and are found in cell lines and on virions at low 
levels. Within the Golgi compartment, maturation of N-linked sugars and addition of O-linked 
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carbohydrates result in a predicted 84-92kDa fully maturated protein (201). Given the 
extensive glycosylation of the G protein, it is unsurprising that the carbohydrate groups 
influence virus infectivity (85, 202) and cell-type specific glycosylation of G has been 
documented to affect the electrophoretic mobility of the G protein (86, 87).  
In the present study, we determine the requirement for G for efficient infection of a 
primary, well-differentiated human airway epithelial culture (HAE) and show that deletion of 
G impairs infectivity and spread of RSV. Next, we examine virus produced in HEp2 and Vero 
cells, both of which are commonly used to amplify RSV in the laboratory. We show that 
ability to infect HAE cultures differs greatly based upon cell line used to amplify virus. 
Biochemical comparison of virus grown in these two cell lines reveals a smaller form of the 
RSV G protein in virions produced by Vero cells. These results demonstrate the importance 
of the G protein and suggest that the cell lines used to produce a virus can alter its 
infectivity. Because Vero cells are necessary for growth of RSV mutants, yet virions derived 
from Vero cells are less able to infect HAE, we produced a HEp-2 cell line stably expressing 
an interferon antagonist and show that RSV mutants grow to high titers in this cell line. 
 
2.3 Results 
Requirement for RSV G in infection of human airway epithelial cultures 
 We and others have demonstrated that the RSV glycoprotein (G) is not required for 
infectivity in tissue culture cell lines (70). Because deletion of G has been shown to 
attenuate RSV in vivo (203), we determined the requirement of G for RSV infection of a 
primary well-differentiated model of the human airway epithelium (HAE). RSVΔG infected 
fewer numbers of cells at 24 hours pi compared to RSV and analysis of percentage of GFP-
positive epithelium demonstrated a 20-fold decrease in initial infection of HAE (Figure 2.1). 
RSVΔG was also attenuated for secondary infection and spread in HAE, reaching peak 
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titers at a later time compared to RSV (4 days vs 3 days, respectively) and infecting only 
37% of the surface epithelium at the time of peak infection compared to 83% GFP positive 
epithelium at peak infection with RSV (Figure 2.1B).  
Impact of G phenotype on infection of HAE 
 Post-translational processing and glycosylation is important for the attachment 
functions of G and processing intermediates ranging from an immature 45 kDa form to the 
fully O-glycosylated, mature 90 kDa form of G have been described in infected cells (86, 87). 
To assess the size of G on virus grown in HAE, we purified virus from apical washes of HAE 
infected with RSV and compared the electrophoretic mobility to virus grown in HEp2 or Vero 
cells. As predicted, the mature 90 kDa form of G was detectable on HEp2-derived virus. 
Vero-derived virus, however, primarily contained the 55 kDa G protein.  Western blotting of 
HAE-grown virions reveals a novel form of G migrating at approximately 180 kDa, in addition 
to a smaller amount of the 90 kDa form found in HEp2-derived virus (Figure 2.2A). This 
larger form of G is likely either a dimer of the 90 kDa form found in HEp2 cells or represents 
additional post-translational modification and more extensive glycosylation unique to the 
maturation of G in ciliated cells.  
 Differences in post-translational modification of G have been noted in in cell lines to 
affect the attachment function of G and infectivity of RSV (85, 202). HEp2 and Vero cell lines 
are most frequently used to amplify RSV, although the size of G is smaller from Vero-
derived virus compared to HEp2-derived virus. To assess if this difference in G impacts RSV 
infection of HAE, we infected HAE cultures with equal inoculums of RSV amplified in HEp2 
cells or Vero cells. Initial infection of HAE with Vero-derived RSV was significantly 
decreased compared to HEp2-derived RSV (Figure 2.2B). At 1 day pi, <1% of the HAE 
surface infected with Vero-derived RSV was GFP positive, compared to 40% GFP positive 
surface epithelium infected with HEp2-derived RSV at the same timepoint. After a single 
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round of infection, however, Vero-derived RSV replicated and spread with kinetics similar to 
HEp2-derived RSV. Although attenuated at 1 day pi, Vero-derived RSV reached infection 
levels almost equal to HEp2-derived RSV, resulting in ~70% GFP positivity of the HAE 
apical surface at the time of peak infection compared to ~80% GFP positive epithelium at 
the time of peak infection with HEp2-derived RSV (Figure 2.2B). Similar infection kinetics 
following the first round of infection is expected, as the form of G on the virion surface of 
virus produced by HAE cells would be similar, regardless of the cell line used to amplify the 
original inoculum. 
Development and characterization of HEp2-V cell line 
 Vero cells, which lack the genes encoding IFN-α and –β, are frequently used to grow 
viruses containing attenuating mutations. RSV encodes two major IFN antagonist proteins, 
NS1 and NS2, and deletion of either or both of these genes results in severe attenuation of 
the virus in cell lines (104). Similarly, infection of HAE with these viruses results in severe 
attenuation of replication and spread (Figure 2.3). RSVΔNS1 infection results in only 1-4% 
of GFP positive apical surface area during 8 days of infection, while 16% of the airway 
surface was GFP positive at peak infection of RSVΔNS2. In contrast, RSV infected and 
replicated efficiently in HAE, resulting in 73% GFP positive surface area at 3 days pi, the 
time of peak infection. 
Vero cells are commonly used to amplify the RSVΔNS1 and RSVΔNS2 mutant 
viruses to sufficiently high titer for study. However, we have demonstrated that amplification 
of virus in Vero cells results in initial attenuation of infection. We have therefore identified a 
need for a cell line capable of producing virus with the mature form of G while also able to 
amplify RSV lacking the type I IFN antagonism genes to high titers. To this end, we stably 
transformed HEp2 cells with the IFN antagonist V protein from SV5. HEp2 cells stably 
expressing SV5 V (HEp2-V cells) were assessed for V expression and inhibition of type I 
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IFN signal transduction. V was detected at high levels in whole cell lysates of HEp2-V cells, 
confirming robust expression (Figure 2.4A). To characterize type I IFN signal transduction in 
HEp2-V cells, we measured IFNβ gene message levels following treatment of HEp2 and 
HEp2-V cells with exogenous recombinant IFNβ for 24 hours. Exogenous IFNβ treatment 
stimulated a 8-fold increase in IFNβ message in HEp2 cells, while no changes were 
detected in HEp2-V cells (Figure 2.4B). To assess the type I IFN response of HEp2-V cells 
to viral infection, we infected HEp2 and HEp2-V cells with Sendai virus (SeV), a virus known 
to stimulate a robust type I IFN response. SeV infection resulted in a 30-fold increase IFNβ 
gene expression in HEp2 cells compared to mock inoculated cells (Figure 2.4C). Type I IFN 
secretion following SeV infection was also measured by bioassay (Figure 2.4D). HEp2 cells 
secreted high levels of type I IFN 24h following SeV inoculation, while no significant 
increases in IFN secretion from SeV-infected HEp2-V cells was detected. SeV infection 
resulted in equal numbers of infected cells in both HEp2 and HEp2-V cells (data not shown). 
We therefore conclude that stable expression of V in HEp2 cells significantly reduces the 
type I IFN response of this cell line. 
RSV and RSV deleted for the NS1 and NS2 genes, individually (RSVΔNS1 and 
RSVΔNS2) and together (RSVΔNS1/2), were amplified in HEp2 cells, HEp2-V cells, and 
Vero cells and concentration of virus recovered, expressed as plaque forming units (PFU) 
per ml, was assessed for each cell line (Table 2.1). In HEp2 cells, RSVΔNS2 replicated to 
titers 1.5 logs lower than RSV. RSVΔNS1 and RSVΔNS1/2 grew to even lower titers and 
>103 PFU/ml was recovered in HEp2 cells. In Vero cells, all viruses were amplified to 
roughly equal levels, producing 2-6 x106 PFU/ml. In HEp2-V cells, all viruses were amplified 
to ~1-log greater concentration compared to amplification in Vero cells. RSV was recovered 
at the highest titer in HEp2-V cells (9x107 PFU/ml). Greater than 4 logs more virus was 
recovered when RSVΔNS1 and RSVΔNS1/2 were amplified in HEp2-V cells compared to 
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HEp2 cells. The ability to amplify attenuated RSV mutants to high titers in a cell line that 
produces a G protein conducive to efficient initial infection will allow for future studies with 
attenuated RSV mutants in HAE. Importantly, these findings confirm that inactivation of the 
type I IFN response is essential for productive RSV infection and that the NS1 and NS2 
proteins are required for attenuation of this response. 
 
2.4 Discussion 
The RSV glycoprotein (G) and fusion protein (F) mediate attachment and entry of 
RSV to the target ciliated cell. RSV binding and entry is a two-step process, whereby the 
virion first attaches to the cell membrane followed by a fusion event. In cell line models of 
infection, the F protein is sufficient for binding and entry of RSV and, although the G protein 
enhances attachment, G is not considered required (71). In HAE, we demonstrated that 
RSV deleted for the G protein is significantly attenuated for initial infection and subsequent 
spread throughout the culture, suggesting a heightened requirement for RSV G for efficient 
in vivo infection. G-mediated attachment to cultured cells is dependent on 
glycosaminoglycans (GAGs) on the cell surface, most notably heparan sulfate (HS), and 
likely involves electrostatic interaction between G and GAGs, though requirements for GAG 
structural elements have been noted (76-79). Although interactions between G and HS have 
been well documented, HS is not detectable on the surface of primary well-differentiated 
models of the human airway epithelium (81), suggesting that G may interact with other 
GAGs present at the apical cell surface, such as keratan sulfate, or that GAG binding is not 
important for the attachment function of G in vivo.  
In these studies, biochemical characterization of G on the surface of virus produced 
by Vero cells, HEp2 cells, and HAE cultures demonstrated different electrophoretic mobility 
of G, suggesting differences in the maturity and processing of G during infection of these 
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cell-types. G contains 7 N-linked glycosylation sites and 24-25 O-linked glycosylation sites 
and it has been estimated that approximately half of the final 90 kDa molecular mass of 
mature G is due to O-linked glycosylation (85). Cell-type specific differences in 
electrophoretic mobility of G have been documented and associated with differences in 
glycosylation patterns (86, 87). We found that the 55 kDa form of G is predominant on virus 
derived from Vero cells and likely represents a processing intermediate, although differential 
cleavage of G may also result in this form. The 90 kDa protein on virus derived from HEp2 
cells is the mature, fully glycosylated form. Interesting, these studies reveal a larger form of 
G on virus produced by ciliated cells in HAE cultures. This 180 kDa form of G may be a 
homodimer of the same form of G found on HEp2-grown virus. An unglycosylated region in 
G contains four cysteines held together by disulfide bonds followed by a predicted heparin-
binding domain (204-206). Dimerization via this region may make the G homodimer resistant 
to reduction during Western blot analysis, allowing for electrophoretic mobility in the 180 
kDa range. Alternatively, the 180 kDa form of G may have additional or more extensive O-
linked carbohydrate chains added during processing of G in the ciliated cell. 
Maturation of G is associated with infectivity in cell lines (76, 85). Similarly, we found 
that the size of G greatly impacted RSV infectivity of HAE cultures, as viruses containing 
mature G derived from HEp2 cells are more infectious than viruses containing the smaller 
form of G derived from Vero cells. The impact of the increased size of G from viruses grown 
in HAE was not evaluated and future studies will aim to determine the glycosylation pattern 
of G and infectivity of virus from HAE. 
Vero cells are the only cell line approved by the World Health Organization for 
production of live-attenuated or inactivated vaccines. However, we found that infectivity HAE 
with RSV grown in Vero cells was significantly reduced compared to that of RSV grown in 
HEp2 cells. It is reasonable to speculate that attenuated vaccine candidates amplified in 
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Vero cells might infect humans inefficiently as well. In trials of attenuated vaccine 
candidates, escalating doses are used to identify the lowest dose that induces an adequate 
antibody response. Although Vero cell-grown attenuated vaccine candidates induce 
neutralizing antibodies in infants, we predict that vaccine candidates produced in a different 
cell line would require less inoculum to induce an equal antibody response. A lower 
inoculum may reduce side effects and respiratory symptoms that have plagued similar 
vaccine candidates and resulted in discontinuation. Lower inoculum would reduce exposure 
to non-replicating viral antigens, cell culture derived cytokines and chemokines, and other 
possible contaminants that may contribute to inflammation and respiratory symptoms of 
vaccinated infants. Attenuating changes in processing and glycosylation of viral attachment 
proteins of viruses produced in Vero cells may impact infectivity and immunogenicity of 
additional respiratory viral vaccine candidates as well.   
Due to the absence of IFN-α and –β genes, Vero cells are also extensively used in 
the laboratory to amplify viruses containing attenuating mutations. Indeed, we use Vero cells 
to amplify RSVΔNS1, RSVΔNS2, and RSVΔNS1/2 to sufficiently high inoculum for study in 
cell lines and HAE. These studies, however, indicate that RSV gene deletion mutants 
derived from Vero cell may be doubly attenuated. First, the G protein on these viruses does 
not allow for efficient initial infection of HAE cultures, resulting in fewer cells infected at day 
1 pi. Second, deletion of the NS proteins results in attenuated replication due to loss of type 
I IFN antagonism, leading to decreased replication and spread. Such low numbers of 
infected cells hamper studies of these deletion mutants in HAE. Thus, a cell line that would 
result in proper processing of G, allowing for efficient initial infection, while also supporting 
replication of attenuated viruses to high titers is needed.  
To address this need, we engineered Hep2 cells to be nonresponsive to IFN by 
stable expression of the IFN antagonist V protein of SV5, which blocks type I IFN signaling 
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by promoting degradation of STAT1 (207, 208). The engineered cell line HEp2-V 
demonstrated decreased IFN responses to exogenous recombinant IFNβ or infection with 
Sendai virus and supported viral replication, producing high viral yields of all RSV mutant 
viruses. 
Generation of cell lines which cannot respond to IFN may have direct relevance for 
vaccine development and laboratory amplification of viruses. Such IFN-nonresponder cell 
lines yield significantly higher titers of viruses, especially those that grow poorly in tissue 
culture due to attenuating mutations, and may be useful for production of live attenuated 
vaccine candidates. While Vero cells are currently used for this purpose, generation of an 
alternative cell line may produce higher yields and more infectious virus. Additionally, the 
IFN response is a major constraint preventing animal viruses from replicating in human cells, 
where function of IFN resistance genes is hindered due to species differences. For example, 
bovine RSV (bRSV) shows increased sensitivity to human IFN compared to human RSV 
and functional differences have been identified in the IFN antagonist proteins of bRSV 
compared to human RSV (209, 210). Therefore, cell lines nonresponsive to IFN may be 
used to isolate and amplify animal viruses or cultivate viruses that grow suboptimally in 
currently available cell lines. 
In summary, optimal RSV infection of the human airway epithelium requires the 
mature G protein and initial infection of HAE with viruses derived from Vero cells is 
inefficient due the predominance of a smaller form of G on the virus surface. To facilitate 
efficient infection of attenuated mutants of RSV, we engineered the HEp2-V cell line, which 
produced high yields of RSV NS deletion viruses and may be used to effectively amplify 
IFN-sensitive viruses for future study. Finally, these studies confirmed the importance of the 
RSV NS1 and NS2 proteins in circumventing the type I IFN response during the RSV life-
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cycle, as the attenuated replication phenotype of RSV NS1 or NS2 deletion mutants was 
almost completely rescued in IFN nonresponsive cell lines. 
2.5 Materials and Methods 
Cells 
Human airway epithelial cells were isolated by the UNC Cystic Fibrosis Center Cell Culture 
and Tissue Procurement Core from tracheobronchial airway specimens obtained from 
patients provided by the National Disease Research Interchange (NDRI, Philadelphia, PA) 
or as excess tissue following lung transplantation. All protocols were approved by the 
University of North Carolina at Chapel Hill Institutional Review Board. Primary epithelial cells 
derived from single patient sources were plated on permeable Transwell-Col supports (12-
mm diameter, Corning, Inc.) and grown in custom media at an air-liquid interface for 8 to 10 
weeks to form differentiated, polarized cultures as previously described  (211). HEp-2 
(ATCC, Manasass, VA) cell lines were grown in MEM (Gibco), 10% fetal bovine serum 
(FBS) and Vero cell lines in DMEM (Gibco), 10% FBS. Cells were incubated at 37oC in 5% 
CO2. 
Viruses  
Recombinant GFP-expressing RSV used in these experiments were RSV (strain A2) 
and mutants of this virus lacking the G glycoprotein genes designated RSVΔG (71). These 
viruses were provided by Drs. Mark Peeples and Steve Kwilas. Recombinant RSVΔNS1, 
RSVΔNS2, and RSVΔNS1/2 are derivatives of the A2 strain and were constructed and 
described previously (105, 106, 212, 213). These viruses were provided by Dr. Peter 
Collins. Each of these constructs express the green fluorescent protein (GFP) gene as an 
additional gene inserted between the RSV phosphoprotein (P) and matrix (M) genes. 
Recombinant Sendai virus (SeV) expressing GFP were described previously (214). All virus 
stocks and cells tested negative for mycoplasma by PCR (Intronbio, Seongnam-Si, Korea).  
33 
 
Virus inoculation and titer 
HAE cultures were rinsed with PBS 3 times over a 30 min period to remove apical 
secretions, and supplied with fresh basolateral media prior to inoculation. The virus 
inoculum was diluted to 6.2 x 106 pfu in100 μl HBSS (MOI ~10), applied to the apical surface 
of the HAE cultures for 2 hr at 37oC, after which the inoculum was removed by aspiration 
and cultures were incubated at 37oC. At indicated times post-inoculation, images were 
obtained using a Leica DMIRB inverted fluorescence microscope equipped with a cooled-
color charge-coupled-device digital camera (Retiga 1300; QImaging, Burnaby, BC, Canada). 
The proportion of the epithelium positive for GFP was determined by pixilating a black and 
white image, inverting the image, and calculating the percent black pixels by computer for 5 
images per culture and averaging. 
For growth of viruses in different cell types, monolayers of Vero, HEp2, or HEp2-V 
cells in 10cm dishes were washed with PBS and infected at a multiplicity of infection of 0.01 
PFU per cell for 2 hours at 37oC. Inoculum was aspirated, cells were washed and 10ml fresh 
media was added, and cells were incubated at 37oC for 3 days. To harvest virus, cell 
monolayers were scraped and combined with cell supernatant and vortexed at high speed to 
release cell-bound virus. Supernatant was clarified of cell debris by centrifugation and 
concentration of virus was determined on Vero cells by titration and counting GFP-positive 
cells 24 h post-inoculation. 
Construction of HEp2-V cells 
HEK 293 cells were transfected with the plasmids pdlNot1’SV5V’IRESpuro 
(described in (210)), pCMVR8.91, and pMD.G and, after 2 days, lentivirus in the supernatant 
was collected and purified by centrifugation. HEp2 cells were transformed with SV5V 
lentivirus and cultured in the presence of 1.25ug/ml puromycin to select for transformed 
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cells. HEp2-V cells were maintained in MEM (Gibco) supplemented with 10% FBS and 
1ug/ml puromycin. Plasmids were provided by Drs. Richard Randall and Daniel Young. 
Western blot 
 Virus produced from HEp2 and Vero cells was collected in tissue culture 
supernatants. Virus produced from HAE cultures was collected by performing apical surface 
washes with 300 μl of serum-free DMEM (Gibco) harvested at 30 min at 37oC. Samples 
were cleared of cell debris by low speed centrifugation, then lysed and reduced. Proteins 
were separated by electrophoresis on a 10% polyacrylamide gel containing sodium dodecyl 
sulfate (SDS-PAGE) (Invitrogen). Proteins were transferred to a nitrocellulose membrane 
(Invitrogen) and blocked with 5% non-fat milk-0.1% Tween 20. G protein was visualized by 
probing with the L9 antibody that recognizes the conserved central region of the G protein 
(215), followed by HRP-conjugated secondary (Jackson ImmunoResearch) and developed 
with SuperSignal West Pico Chemiluminescent Substrate (Pierce) and exposed to film. The 
L9 antibody was provided by Dr. Edward Walsh. 
IFN bioassay 
Type I IFN secretion produced by HEp2 and HEp2-V cells was determined by IFN 
bioassay as previously described (125). Briefly, clarified cell culture supernatants were 
treated at pH 2.0 at 4oC for 24h to inactivate virus and acid-labile type II IFN, and the pH 
was adjusted to 7.0. Type I IFN concentration was determined by measuring the restriction 
of replication of EMCV on A549 cell line monolayers after 24h in comparison to a known 
concentration of recombinant human IFNβ (Invitrogen). IFNβ standard and supernatants 
were serially diluted in duplicate in 96-well plate of A549 cells. At 24h pi, cells were washed 
and infected with EMCV at MOI = 5. After 24h of infection, bioassay plates were scored for 
50% cytopathic effect as an indicator of IFN concentration. The deduced IFN concentrations 
in test samples were expressed as international unit (IU) per ml. 
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qRT-PCR 
The levels of IFNβ mRNA in cells infected with SeV or treated with rhIFNβ were 
determined by quantitative reverse transcription (qRT)-PCR. Total intracellular RNA was 
extracted using the RNAeasy total RNA cell isolation kit (Qiagen). RNA was reverse 
transcribed using an oligo (dT) primers and SuperScript II reverse transcriptase (Invitrogen). 
Real-time PCR was performed using Taqman gene expression assays and an Applied 
Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems). Each sample was 
internally normalized to GAPDH housekeeping gene. Signals from virus-infected or IFNβ-
treated samples were expressed as fold change over mock-inoculated or untreated 
samples. 
Statistical analysis 
Unpaired t-test and one-way analysis of variance (ANOVA) with Tukey’s post-test 
was performed as indicated. Statistical significance was defined as P<0.05 unless otherwise 
noted. 
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Figure 2.1. RSV requires the G protein for efficient infection of HAE. (A) Representative 
en face fluorescent images of HAE infected with RSVΔG (i) or RSV (ii) at 1 day pi. Both 
viruses express GFP. Scale bar represents 10 µm. (B) The number of cells in HAE infected 
over time by RSV (closed circles) or RSVΔG (open triangles), quantified as the percentage 
of the epithelium surface area positive for GFP fluorescence. Data (mean ± SEM) are n = 4 
cultures. 
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Figure 2.2 Infection of HAE with RSV amplified in Vero cells or HEp2 cells. (A) Western 
blot assay of virus released from HEp2 cells, Vero cells, or HAE cultures, probed with the L9 
antibody to detect G. (B) The number of cells in HAE infected over time by RSV amplified in 
HEp2 cells (closed circles) or RSV amplified in Vero cells (open squares), quantified as the 
percentage of the epithelium surface area positive for GFP fluorescence. Data (mean ± 
SEM) are n = 4 cultures. 
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Figure 2.3 Infection of HAE with RSV NS deletion mutants. The number of infected cells 
over time was quantified as the percentage of the epithelium surface area positive for GFP 
fluorescence in HAE inoculated with RSV (circles), RSVΔNS1 (squares), or RSVΔNS2 
(triangles). All viruses express GFP. Data (mean ± SEM) are representative of independent 
experiments utilizing n = 3-4 cultures per donor obtained from 3 different donors. 
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Figure 2.4 Characterization of HEp2-V cells. HEp2 cells were stably transfected with V 
from SV5. (A) Western blot analysis of whole cell lysates from HEp2 cells or HEp2-V cells 
probed with an antibody to detect the V protein. Detection of actin was used as a loading 
control. (B) Expression levels of IFNβ from HEp2 and HEp2-V cells treated with exogenous 
recombinant human IFNβ (rhIFNβ). Total RNA was extracted from cells without treatment or 
treated for 24 hours with 1000 IU rhIFNβ and gene expression levels were measured by 
qRT-PCR. Each sample was normalized to GAPDH and is expressed as fold change 
compared to untreated samples. Data (mean ± SD) represent n = 3 experiments. (C) IFNβ 
expression was measured as in (A) following infection with Sendai virus (SeV) at 24h pi. 
Data (mean ± SD) represent n = 3 experiments. (D) Type I IFN secretion from HEp2 and 
HEp2-V cells was determined by IFN bioassay following infection with SeV at 24h pi. Data 
(mean ± SD) represent n = 2 experiments For (B) – (D) significant changes in mRNA or 
secreted type I IFN between treated HEp2 compared to treated HEp2-V cells were 
determined by unpaired t test. *P<0.05 
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Table 2.1 Amount of infectious virus produced from HEp2, Vero, or HEp2-V cells.  
 
Virus 
Concentration of virus (PFU/ml) produced from: 
HEp2 Vero    HEp2-V 
  RSV 5 x 106 2 x 106 9 x 107 
  RSVΔNS1 < 103 6 x 106 3 x 107 
  RSVΔNS2 2.5 x 105 5 x 106 5 x 107 
  RSVΔNS1/2 < 103 2 x 106 3 x 107 
 
 
 
 
 
 
 
 
 
 
  
 
CHAPTER III 
THE RSV NS2 PROTEIN PROMOTES CYTOPATHIC EFFECT OF COLUMNAR CILIATED 
AIRWAY EPITHELIAL CELLS FOLLOWING RSV INFECTION  
 
3.1 Overview 
Respiratory syncytial virus (RSV) infection is the most important cause of 
bronchiolitis in infants and young children worldwide. However, the mechanisms by which 
RSV causes more severe disease compared to other commonly encountered respiratory 
viruses are poorly understood. In this study, we use a primary well-differentiated model of 
the human airway epithelium (HAE) to investigate the consequences of RSV infection of 
ciliated cells, the target cell population in HAE. These results show striking resemblance to 
RSV infection in infant lungs. Namely, infection was restricted to ciliated cell types, induced 
gene transcription of antiviral cytokines, caused rounding of infected cells, and resulted in 
shedding of infected cells from the airway epithelium. We further identify the RSV non-
structural 2 (NS2) protein as a unique viral genetic determinant for RSV-induced cell 
rounding, cilia degradation, and cell shedding. Sloughing of infected cells has been noted in 
infants with severe RSV-bronchiolitis, indicating that cell shedding occurs in vivo to enhance 
RSV disease and suggesting a previously unrecognized role for NS2 in RSV pathogenesis. 
 
 
 
 
 
 
 
___________________________ 
Sections of this chapter are under review for publication in the Journal of Clinical Investigation. 
43 
 
3.2 Introduction 
RSV is the most common virus causing acute and severe lower airway disease in 
infants and young children. RSV infection is responsible for spectrum of diseases ranging 
from upper respiratory tract illness resulting in common cold-like symptoms to severe lower 
respiratory tract illness resulting in bronchiolitis and pneumonia. In ~2% of cases, lower 
airway disease is severe enough to require hospitalization (5). Globally, an estimated 34 
million new pediatric cases of RSV-associated lower airway disease occur annually 
accounting for approximately 200,000 deaths, almost all occurring in developing countries 
with reduced access to standardized care (4). Despite the obvious impact of RSV infection 
on infant morbidity and mortality, treatment options remain limited to supportive care and no 
licensed RSV vaccine is currently available. The high incidence of RSV infection and the 
potential for severe distal airway disease in vulnerable young children combined with limited 
availability of therapeutic options identifies a significant clinical global need to reduce the 
burden of RSV-associated disease. 
RSV infects the mucosal epithelium lining the human respiratory tract, predominantly 
targeting the columnar epithelial cells of the conducting airways. In addition to providing a 
physical barrier to prevent penetration of pathogens, the columnar airway epithelium serves 
a mechanical innate defense function for clearing airways of inhaled pathogens by 
generating unidirectional mucus transport out of the airways, facilitated by synchronous cilia 
beat and regulated mucin secretion.  Precisely how RSV infection affects innate function of 
the columnar airway epithelium and how infection of columnar epithelial cells relates to 
subsequent RSV-associated disease is poorly defined.  
Severe RSV-associated bronchiolitis is characterized by wheezing, increased airway 
resistance, atelectasis, and hyperinflation (216). Increased proinflammatory cytokines, 
especially IL-8 and IL-1β, in nasophyngeal secretions and bronchoalveolar washes 
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positively correlated with disease severity (118, 133, 144). Histologic analyses of autopsy 
lung tissues from RSV-infected infants described epithelial cells sloughed into the airway 
lumen (117, 119, 161). Although the contribution of these sloughed cells to exacerbation of 
RSV-associated bronchiolitis was unclear, it was speculated that these intralumenal 
accumulations of infected and necrotic epithelial cells could contribute to airway obstruction 
and inflammation. 
The majority of studies on RSV pathogenesis utilized tissue culture cell lines or small 
animal models. Although these studies have provided valuable insight into RSV biology, the 
majority of animal models are only semi-permissive to RSV infection and cell lines do not 
accurately represent the highly polarized and structured nature of the ciliated cell, the target 
of RSV infection. Therefore, there is a need for a more complete understanding of the 
effects of RSV on the human airway epithelium. We have previously described an in vitro 
model of RSV infection of human cartilaginous airway epithelium (HAE) that recapitulates 
the cellular distribution and physiology of the human differentiated airway epithelium. Using 
this model, we and others have shown that RSV preferentially infects ciliated epithelial cells 
in HAE yet we are unable to detect infection of mucin-containing Goblet cells and basal cells 
(114, 115). Histologic studies of upper airways from RSV-infected patients also demonstrate 
the preferential tropism of RSV for ciliated cells, supporting our in vitro findings (117).  
Our previous studies demonstrated RSV infection of human ciliated cells in HAE was 
minimally cytopathic, at least within the first 48h of infection (115). The lack of direct RSV-
induced cytopathology was in contrast to the rapid and robust cytopathology documented in 
HAE infected by influenza viruses (217). We now expand our earlier studies with RSV to 
track the fate of RSV-infected ciliated cells over time to determine consequences of infection 
potentially important for pathogenesis. By determining the fate of RSV-infected ciliated cells 
in vitro, we identify a unique consequence of RSV infection whereby infected ciliated cells 
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rapidly transition from a columnar to a rounded cell morphology and are then extruded from 
the otherwise intact epithelium, resulting in detached, viable, virus-infected epithelial cells in 
the lumenal secretions of HAE. Using RSV gene deletion mutants, we attribute the function 
of cell rounding to the RSV non-structural 2 (NS2) protein. Gain-of-function experiments 
using recombinant parainfluenza virus (PIV3-GFP) engineered to express RSV NS2 (PIV3-
NS2) demonstrated that ciliated cells infected by PIV3-NS2, but not PIV3, became rounded 
and morphologically indistinguishable from RSV-infected ciliated cells. These studies 
provide the first description of the unique fate of RSV-infected columnar airway epithelial 
cells and identify the expression of a single RSV protein, RSV NS2, as promoting this event.  
 
3.3 Results 
Kinetics of RSV replication in HAE  
The kinetics of RSV infection of HAE were measured by inoculating the apical 
surface of cultures with a recombinant RSV expressing GFP inserted between the P and M 
genes (3x105 PFU; MOI ~1), and the numbers of GFP-positive cells and titers of released 
virus were determined every 24 h for 8 days. Representative en face images of GFP-
positive cells and quantification of the percentage of epithelium surface area positive for 
GFP across HAE obtained from multiple tissue donors are shown in Figure 3.1A and 3.1C, 
respectively. At 1 day post-inoculation (pi), RSV infection resulted in 5% of the epithelium 
surface area positive for GFP and over time the extent of infection steadily increased as 
virus infection spread, with 53% of the epithelium surface area being GFP-positive by day 4 
pi. Beyond 4 days pi, the numbers of GFP-positive cells declined rapidly and by day 8 pi, the 
extent of infection approximated the level of infection at 1 day pi. In agreement with previous 
studies, throughout infection, only ciliated cells expressed GFP, confirming RSV tropism for 
ciliated cells in this model. On average, ciliated cells represented ~90% of the surface 
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columnar epithelial cells in HAE, indicating ~60% of available ciliated cells were infected by 
RSV at the time of maximal infection (day 4).  
RSV titers in washes harvested from the apical surfaces of HAE paralleled the 
numbers of GFP-positive cells (Figure 3.1D). RSV titers steadily increased proportionate to 
the numbers of GFP-positive cells during the first 3 days of infection, reaching maximal titers 
by 4 days pi (2.6x106 PFU/ml). Once maximal, virus titers declined proportionate to the loss 
of GFP-positive cells and, by 8 days pi, virus titers had fallen by 2 logs compared to those at 
4 days pi (Figure 3.1D). The rapid net loss of RSV infection from HAE between 4 and 8 days 
pi suggests most of the RSV-infected ciliated cells were cleared from the epithelium during 
this period and, as HAE are pure populations of epithelial cells, that clearance of infected 
ciliated cells occurred in the absence of immune cell-mediated clearance mechanisms. 
HAE cultures remained intact based on gross visual inspection, as previously 
described (115, 125).  ZO-1 staining on uninfected and RSV infected ciliated cells indicated 
that tight juctions and membrane barrier integrity remained intact (Figure 3.1B). 
IFN and cytokine message following RSV infection  
 To characterize the innate immune response of the ciliated airway epithelium, we 
analyzed IFNβ and cytokine message levels over time following RSV infection of HAE 
compared to inoculation with UV-inactivated RSV. Because these cytokines are increased in 
RSV infection of both tissue culture cells lines as well as infants with severe disease (118, 
136, 142, 143), we chose to analyze IFNβ, CXCL10, IL-1β, IL-8, RANTES, and TNF-α 
(Figure 3.2). At 1 day pi, IFNβ, CXCL10, and RANTES were significantly increased 
compared to UV RSV, and by day 2 pi, all genes except IL-1β were significantly 
upregulated. Transcription of all genes analyzed peaked at 4 days pi, correlating with the 
time of peak infection of HAE, and began to decrease by 5 days pi, correlating with the 
decline in GFP positive epithelium. 
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A distinctive morphologic change in RSV-infected columnar airway cells 
To investigate how RSV-infected (GFP-positive) ciliated cells were cleared from 
HAE, we tracked the fate of infected ciliated cells over time in histologic sections of cultures. 
These studies revealed that RSV-infected ciliated cells underwent a distinctive morphologic 
transition from the native columnar cell morphology to a rounded cell morphology, with 
infected rounded ciliated cells visibly embedded among non-infected columnar cells (Figure 
3.3A). Ciliated epithelial cells in human cartilaginous airway epithelium and in HAE cultures 
are characteristically columnar with individual ciliated cells spanning the depth of the 
epithelium and the ciliated cell tail intercalating into the underlying basal epithelial cell 
layers. We speculate that transition of RSV-infected ciliated cells from columnar to rounded 
cell morphology likely involves release of the ciliated cell tail from the basal epithelial cell 
layer, resulting in the infected cell assuming a rounded shape. Only those ciliated cells that 
were GFP-positive (i.e., infected with RSV) exhibited rounded cell morphology, and no GFP-
positive cells were observed that retained the native columnar shape of ciliated cells, 
suggesting that ciliated cell rounding was a direct consequence of RSV infection. 
Ciliated cells infected by RSV also, over time, began to bulge from the epithelial layer 
into the lumenal compartment (Figure 3.3A). The bulging apical membranes of RSV-infected 
cells also progressively lost apical structural markers characteristic of ciliated cells, including 
cilia, as demonstrated by loss of beta-tubulin IV immunoreactivity (Figure 3.3Aiv-vi) and a 
marked thinning of the cytoskeletal terminal web of ciliated cells (see arrows, Figure 3.3Ai 
and iii).  Despite significant disruption of apical membrane structures in these bulging 
ciliated cells, the cells retained GFP fluorescence, suggesting plasma membrane 
permeability was not overtly compromised (Figure 3.3Aiv-vi).  High power transmission 
electron microscopy (TEM) studies of non-infected and RSV-infected HAE, fixed to preserve 
the hydrated external environment of the HAE lumenal surface, confirmed that RSV infection 
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resulted in the disintegration of apical membrane structures, most notably cilia shafts and 
microvilli (Figure 3.3B). Cytoplasmic cilia basal bodies, usually organized directly below 
emerging cilia shafts, were often disorganized in RSV-infected ciliated cells (Figure 3.3Biii, 
star).  Clouds of particulate matter in the external lumenal environment were composed of 
fragmented cilia and microvilli directly above bulging RSV-infected ciliated cells (Figure 
3.3Bii). It is reasonable to presume that these particulate clouds also contain progeny RSV 
virions and, on occasion, structures resembling RSV virions could be detected (Figure 
3.3Biii, arrow). More direct identification of RSV virions in these clouds was technically 
challenging, as immunogold labeling of virus proteins would not discriminate between 
infectious progeny virions and virus proteins associated with fragmented cellular debris. 
Shedding of epithelial cells from RSV-infected HAE 
To assess the fate of cells extruded from the epithelium, we examined histologic 
sections of non-infected and RSV-infected HAE fixed to preserve airway surface secretions 
that had accumulated over a 5-day period. These studies revealed that accumulated mucus 
secretions in non-infected HAE contained only low numbers of detached epithelial cells 
(Figure 3.4Ai). In contrast, RSV-infected cultures displayed a marked increase in the 
numbers of detached epithelial cells that were embedded in an increased layer of lumenal 
surface mucus secretions (Figure 3.4Aii). Although rounded and extruding epithelial cells 
showed no obvious morphologic evidence of cell death while associated with the epithelium, 
upon becoming fully detached from the epithelium shed cells showed evidence of apoptosis, 
characterized by morphologic criteria including pyknosis, karyorrhexis, and karyolysis. In 
addition to the increased cell content of the lumenal secretions, the epithelium of RSV-
infected cultures became irregular in appearance, largely due to the rounded morphology of 
infected ciliated cells remaining in the intact epithelium. An overall decrease in cilia also was 
noted in the RSV-infected epithelium.  
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We quantified the extent and kinetics of epithelial cell shedding from RSV-infected 
HAE cultures by determining the amount of double-stranded DNA (dsDNA) present in daily 
washes of the lumenal surfaces of non-infected and RSV-infected HAE (Figure 3.4B). Apical 
washes consistently contained an increased amount of dsDNA at day 1 pi for both non-
infected (mock-inoculated) and RSV-infected HAE, which we attribute to consequences of 
the inoculation procedure. However, by day 3 pi, there was a clear separation in the amount 
of dsDNA present in apical washes between RSV-infected and non-infected HAE, with 
amounts of dsDNA consistently increasing in the RSV-infected HAE cultures and reaching 
maximal levels at 5-7 days pi. In contrast, the amounts of dsDNA in apical washes from non-
infected HAE remained low and constant over the same time period. The increased dsDNA 
in apical washes closely correlated with the loss of GFP-positive epithelial cells from HAE 
(Figure 3.1B), indicating the usefulness of dsDNA as a marker for the numbers of shed 
epithelial cells in airway secretions in vitro.   
Overall, these observations suggest that the loss of GFP-positive cells from RSV-
infected HAE is predominately due to extrusion or shedding of the infected ciliated cells from 
the airway mucosa. While our studies clearly show that epithelial cells display signs of cell 
death after being shed, we were unable to determine the precise kinetics of cell death upon 
detachment of individual cells from the epithelium. We propose that RSV-infected ciliated 
cells remain viable during the shedding process and, once shed, undergo the process of 
detachment-induced apoptosis known as anoikis. Since the reduction of RSV titers in HAE 
paralleled the loss of GFP-positive cells, we propose that RSV-induced shedding of ciliated 
cells represents a primary mechanism for clearing RSV infection from a differentiated airway 
epithelium, at least in vitro. 
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Effects of RSV infection on mucociliary transport 
Extensive shedding of cells onto the lumenal surface of RSV-infected HAE suggests 
that, in vivo, this cellular material may be cleared from the airway lumen by mechanical 
clearance mechanisms, such as mucociliary transport and cough clearance. In vitro, we 
often observed GFP-positive cells shed into the HAE lumenal secretions being be 
transported across the surface of cultures. Since directional transport of airway secretions in 
HAE is dependent on coordinated cilia beat, the potential impact of RSV infection on the 
effectiveness of cilia function is an important consideration when assessing the contribution 
of mechanical clearance to resolution of infection. We tested the ability of HAE to perform 
directional transport of particulates present in airway secretions by measuring mucociliary 
transport (MCT) rates of 1 µm fluorescent beads transported across the lumenal surface of 
HAE (Figure 3.4C). For non-infected HAE, MCT rates of ~40 µm/sec were maintained for 6 
consecutive days of experimental analysis. For RSV-infected HAE, MCT rates approximated 
those of non-infected HAE during the first 2 days of RSV infection, despite infection of ~20% 
of the epithelium surface. However, by 3 days pi, RSV-infected HAE demonstrated a 
significant decline in MCT rate and by day 4 pi, when typically ~60% of the epithelium 
surface was infected, MCT rates had fallen drastically to below 5 µm/sec. By 5 days pi, bead 
transport in RSV-infected HAE had ceased.  
To determine whether loss of MCT after RSV infection was directly associated with 
loss of cilia function, we also quantified the percentage of the epithelium surface which 
displayed beating cilia at each time-point (Figure 3.4D). In non-infected HAE, ~90% of the 
epithelium surface displayed active cilia and this level was maintained over 6 consecutive 
days of analysis. A similar extent of cilia activity was measured during the first 2 days of 
RSV infection, indicating that cilia activity of infected cells was not affected early during 
infection, similar to our previous findings (115). However, beginning at 3 days pi, the area of 
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active cilia progressively declined, resulting in only 38% of the epithelium surface displaying 
active cilia by 5 days pi and 10% by 6 days pi. Combined, these results show that within the 
first few days of infection, RSV does not significantly impact the ability of the ciliated 
epithelium to perform MCT. However, as increased numbers of cells were infected and 
infection of individual cells resulted in apical membrane cytopathology, RSV infection can 
abolish MCT. We noted that at 3 and 4 days pi, although the area of cilia activity was high, 
MCT rates had rapidly declined. Such declines in MCT rate prior to significant losses in cilia 
activity may be explained by subtle but deleterious effects of RSV infection on coordinated 
cilia beat, such as cilia beat asynchrony in infected ciliated cells, and subsequent disruption 
of unidirectional transport. Taken together, these data suggest that, at least up until 3 days 
pi, RSV-infected HAE cultures maintain sufficient MCT to transport infected cells shed on to 
the airway surface and that cell shedding followed by MCT may represent a previously 
unidentified mechanism by which RSV infection is cleared from the airways. 
Cell rounding is unique to RSV among a number of common paramyxoviruses 
We also investigated whether the rounding of ciliated cells following RSV infection 
occurs following infection with other respiratory viruses known to infect ciliated cells in HAE. 
Ciliated cells infected by parainfluenza virus (PIV) serotypes 1, 2, 3, or 5, Sendai virus 
(SeV), or human metapneumovirus (HMPV) failed to exhibit ciliated cell rounding (Figure 
3.5A and data not shown). As an index of cell rounding, we measured the height of GFP-
positive cells using confocal microscopy xz sections. Ciliated cells infected by RSV were 
significantly shorter, due to cell rounding, than those infected by the other GFP-expressing 
respiratory viruses that were tested (Figure 3.5Aiv). Although we noted ciliated cells infected 
with PIV3 were somewhat shorter than those infected with PIV5, SeV, or HMPV, PIV3-
infected cells did not exhibit RSV-like rounding of infected cells, and instead appeared to 
remain associated with the underlying basal epithelial cells. Since our studies utilized a 
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recombinant RSV A2 strain expressing GFP, we confirmed that cell rounding was not an 
artifact of the recombinant virus or expression of GFP, as a recombinant RSV without GFP 
(GP1), the biologically-derived RSV from which the recombinant was generated (HEp-4), 
and a wild-type RSV strain of subgroup B all caused rounding of infected ciliated cells 
identical to the recombinant GFP-expressing virus (data not shown). Because studies have 
described phenotypic differences between highly passaged RSV strains and clinical 
isolates, we confirmed that a recently isolated, minimally passaged, clinical strain of RSV 
(RSV Memphis 37) caused infected ciliated cells to round with morphology indistinguishable 
from those cells infected by recombinant GFP-expressing RSV (Figure 3.5Ai and ii). Overall, 
these data suggest ciliated cell rounding is a unique consequence of RSV infection. 
Columnar cell rounding is associated with expression of the NS2 gene 
 We speculated that the unique morphologic phenotype induced in ciliated cells by 
RSV infection might be due to the expression of specific RSV genes. We explored this 
possibility by infecting human ciliated cells with recombinant, GFP-expressing RSVs from 
which individual viral genes had been deleted. These studies revealed that infection of 
ciliated cells by a mutant RSV with deletion of the two non-structural genes, NS1 and NS2 
(RSVΔNS1/2), failed to cause rounding of infected ciliated cells (Figure 3.5Biv). Instead, 
ciliated cells infected with this mutant retained the native columnar morphology and 
resembled the morphology of ciliated cells infected by other respiratory viruses, such as 
PIV3. Evaluation of RSV mutants deleted individually of NS1 or NS2 genes (RSVΔNS1 and 
RSVΔNS2) showed that RSVΔNS1 infection induced ciliated cell rounding in a manner 
indistinguishable from that of RSV expressing a full complement of RSV genes, suggesting 
NS1 was not responsible for the cell rounding phenotype (Figure 3.5Bii and iv). In contrast, 
ciliated cells infected by RSVΔNS2 did not round and instead maintained a columnar 
morphology identical to that after RSVΔNS1/2 infection (Figure 3.5Biii and iv).  These 
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differential effects of the NS deleted viruses were not due to significant differences in mutant 
virus replication, as both RSVΔNS1 and RSVΔNS2 were similarly attenuated for replication 
compared to RSV in cell-lines (104)  and HAE (Figure 2.3). Overall, these experiments 
indicate that expression of NS2, in the context of RSV infection, is necessary for RSV-
induced ciliated cell rounding.  
 To determine if a specific, known domain in the NS2 protein was associated with 
rounding, we infected HAE with a series of mutants containing deletions in the NS2 protein. 
Serial 5 – 10 amino acid deletions were introduced into the NS2 protein, and an N-terminal 
HA tag was added to facilitate detection of the NS2 protein (Figure 3.6B). Deletion of the 
first 20 amino acids of the N-terminus of NS2 had no effect on the ability of the virus to 
cause cell rounding, and cells infected by these mutants were morphologically identical to 
cells infected by wild-type RSV (Figure 3.6A, C NΔ10, NΔ20, NΔ10-20). However, deletion 
of the first 5 amino acids of the C-terminus or deletions within the internal section of NS2 
ablated the ability of RSV to cause infected cell rounding, and the morphology of cells 
infected by these mutants resembled RSVΔNS2-infected cells (Figure 3.6A, C NΔ30-40, 
NΔ40-50, NΔ50-60, NΔ84-94, CΔ10, CΔ5). All deletion mutants were attenuated for 
replication in HAE. Expression of NS2 was confirmed in HEp-2 cells by western blot (data 
not shown). 
Expression of NS2 by recombinant PIV3 mimics RSV-induced cell morphology 
To investigate whether RSV NS2, in the absence of other RSV genes, was sufficient 
to induce rounding of virus-infected ciliated cells, we took advantage of our findings that 
ciliated cells infected by PIV3 retained columnar morphology. Since PIV3, like RSV, 
exclusively infects ciliated cells in HAE cultures, we used PIV3 to deliver RSV NS1, NS2, or 
both genes to ciliated cells in the absence of other RSV genes. We engineered recombinant 
PIV3 containing the GFP gene to express NS2 (PIV3-NS2), NS1 (PIV3-NS1), or both NS1 
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and NS2 (PIV3-NS1/2) and assessed consequences of infection compared to PIV3 
expressing GFP alone.  In each case, GFP was inserted between the P and M genes, and 
the RSV gene(s) were inserted between the HN and L genes. These recombinants were 
readily recovered, and infection and growth was assessed in non-polarized epithelial cell-
lines and HAE cultures. In non-polarized epithelial cell-lines, recombinant PIV3 viruses 
expressing RSV NS genes and GFP were slightly attenuated for growth compared to PIV3 
expressing GFP alone (data not shown). Similar to the phenotype observed in cell lines, in 
HAE, all 3 PIV3 viruses expressing RSV NS genes exhibited modest growth attenuation 
compared to PIV3, despite similar levels of infection at 1 day pi (Figure 3.7A). PIV3-NS2 and 
PIV3-NS1 exhibited similar growth attenuation in HAE, replicating to ~1-log lower titers than 
PIV3 at 3 days pi, the time of peak replication. PIV3-NS1/2 was more severely attenuated, 
producing 2-logs lower titers than PIV3 at the time of peak replication. This observed 
attenuation presumably reflected the increased genome length and gene number of the 
PIV3 viruses with inserted RSV NS genes, although the formal possibility exists that the 
RSV NS proteins had direct inhibitory effects on replication.  
 In HAE cultures, ciliated cells infected by PIV3 or PIV3-NS1 maintained native 
columnar morphology, whereas ciliated cells infected by PIV3-NS2 or PIV3-NS1/2 
underwent cell rounding, with significantly shortened cell heights (Figure 3.7B, C). The 
observation that PIV3-NS1/2 and PIV3-NS2 caused cell rounding indistinguishable from that 
caused by RSV suggested NS2 mediated this effect independent of the expression of NS1 
or other RSV proteins.  
NS2 expression adversely affects lumenal surface structures and functions of ciliated 
cells  
Closer examination of ciliated cells infected by PIV3-NS2 or PIV3-NS1/2 showed that 
the ultrastructural features of the apical domains of infected ciliated cells were altered in a 
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manner similar to RSV-infected cells. Characteristics of RSV-infected ciliated cells such as 
bulging apical membranes, thinning of the terminal web, and loss of cilia and microvilli were 
evident in, and indistinguishable between, cells infected with RSV, PIV3-NS2, and PIV3-
NS1/2 (Figure 3.8A).  
Functional studies were performed to measure the extent of cilia activity in HAE 
infected by recombinant viruses. These results demonstrated that, for the first 4 days pi, 
PIV3-NS2 and PIV3-NS1/2 infection resulted in a marked decline in the surface area of 
epithelium displaying cilia activity (Figure 3.8B). In contrast, PIV3 infection did not cause a 
decline in cilia activity until 5 days pi. PIV3-NS1, despite robust replication, had little effect 
on cilia activity within the 6 days of experimental analysis. These data suggest PIV3 
infection is not as cytopathic to cilia activity as PIV3-NS2, indicating NS2-promoted cell 
rounding may also be associated with disruption of cilia or cilia scaffolding complexes in 
infected cells.  We also noted the reduced cilia cytopathology observed with PIV3-NS1 
infection compared to PIV3, suggesting NS1 may further reduce even the moderate 
cytopathology evident after PIV3 infection. These findings are intriguing as they point to 
divergent effects of RSV NS1 and NS2 on ciliated cell cytopathology.    
IFNβ and cytokine changes in HAE infected by PIV3, PIV3-NS1, and PIV3-NS2 
 PIV3 encodes viral proteins to block cellular innate immune responses, although 
infection of HAE induces cytokine secretion at later timepoints (218). We therefore 
determined if addition of NS1 or NS2 into wild-type PIV3 would have an additive effect on 
suppression of IFN and cytokine expression. Due to subtle but potentially significant 
differences in replication and spread of these viruses, we focused on the early timepoint 18 
hours pi, accounting for changes in gene expression in cells infected prior to several rounds 
of replication and spread.   
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 At 18 hours pi, message for PIV3-N was detectable in HAE infected by PIV3, PIV3-
NS1, and PIV3-NS2, confirming active replication of the virus (Figure 3.9A). Interesting, N 
levels were significantly higher in PIV3-NS2 infected cultures compared to PIV3 despite 
equal inoculum. It is unclear from these studies whether greater numbers of cells were 
infected by PIV3-NS2 or whether PIV3-NS2 message is expressed at greater levels within 
individual cells compared to PIV3 or PIV3-NS1. Infection with each virus resulted in IFNβ 
message levels elevated over mock-infected cultures, although there were no significant 
differences between PIV3, PIV3-NS1, or PIV3-NS2 (Figure 3.9B). IL-8 message levels were 
not elevated over mock-inoculated cultures following infection with PIV3 or PIV3-NS1 
(Figure 3.9C). However, PIV3-NS2 infection resulted in a 15-fold increase in IL-8 message. 
While it is possible that the increase in IL-8 message was a direct result of increased PIV3-
NS2 replication, normalization of IL-8 signal to PIV3 N signal in PIV3-NS2 infected cultures 
resulted in over a 6-fold increase in message. We also found CXCL10 message levels were 
increased following infection with all viruses, though PIV3-NS2 resulted in increased 
message levels compared to PIV3 or PIV3-NS1 (Figure 3.9D) 
 
3.4 Discussion 
In this study, we used cultures of primary human pseudostratified airway epithelial 
cells (HAE), which closely resemble the epithelium of authentic airway tissue, and show that 
RSV infection of human ciliated cells resulted in the development of a rounded cell 
morphology and distinct apical surface cytopathology, followed by extrusion of the infected 
cells from the epithelium. This effect was not observed with PIV3 or several other respiratory 
paramyxoviruses that target ciliated cells. Once shed, RSV-infected epithelial cells became 
incorporated into airway secretions, underwent apoptosis, and were then transported across 
the airway surface by coordinated cilia beat.  
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The use of RSV gene-deletion mutants demonstrated that these effects were 
dependent on the expression of the RSV NS2 protein. Specifically, whereas ciliated cells 
infected by RSV became rounded, ciliated cells infected with RSVΔNS2 remained columnar 
and embedded within the intact epithelium. Because PIV3 also targeted ciliated cells but did 
not cause the cell rounding phenotype, we used PIV3 as a vector to express RSV genes in 
ciliated cells. Infection of ciliated cells in vitro with PIV3 engineered to express RSV NS2 
(PIV3-NS2) resulted in infected cell morphologic changes indistinguishable from ciliated 
cells infected by RSV, whereas cells infected with PIV3 or PIV3-NS1 remained columnar. 
Findings from both RSV deletion mutants and PIV3 expressing individual RSV genes 
indicated that the induction of this novel ciliated cell morphologic phenotype was unique to 
RSV, and that expression of RSV NS2 in the context of an RSV or PIV3 infection was 
sufficient to induce this phenotype in ciliated cells.  
To identify the functional domain within NS2 responsible for cell rounding, we 
infected HAE with RSV containing sequential deletion mutations within the NS2 protein. 
Viruses with deletion of amino acids 30-40, 40-50, 50-60, and 84-94, relative to the N-
terminus of NS2, are unable to induce cell rounding and retain the native columnar 
morphology, identical to cells infected with RSVΔNS2. Although NS2 expression following 
infection of HEp2 cells with these RSV deletion mutants has been confirmed by western 
blot, we have not yet confirmed expression in ciliated cells. Thus, it is also possible that 
deletion of internal sections of the NS2 protein resulted in protein degradation or 
malfunction, resulting in complete loss of NS2 function. Deletion of the first 5 or 10 amino 
acids from the C-terminus of NS2 also results in a loss of cell rounding. Little is known about 
the functional domains within the NS2 protein, although Swedan and coworkers 
demonstrated that deletion of the C-terminal 10 amino acid residues of NS2 abrogated the 
ability of NS2 to decrease STAT2 levels and impaired the NS2-mediated response to 
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exogenous IFNβ (95). Because the C-terminus of NS1 and NS2 are relatively well 
conserved, with both containing the same DNLP amino acid tetramer followed by an 
aromatic residue (F/Y), it would be interesting if these regions had differing signaling 
functions in the context of infection. Future studies of these mutants to determine 
differences in NS2 expression, viral replication, and NS2 function will contribute to the 
understanding of the functions of NS2 in infected ciliated cells.  
Previous studies have demonstrated that the RSV NS proteins enhance viral 
replication. Recombinant RSV deleted for one or both NS genes resulted in viruses with 
severely attenuated growth in vitro and in vivo (93, 107, 219). Deletion of either the NS1 or 
NS2 gene attenuated human RSV in chimpanzees (106, 107). The NS proteins have also 
been shown to interfere with a number of antiviral host responses aimed at reducing the 
extent of virus replication, most notably type I and III interferon (IFN) pathways. The 
mechanisms by which NS1 and NS2 inhibit IFN responses are complex, involving both 
coordinated and independent functions of the NS proteins (93-95, 98, 100). Both proteins 
have also been implicated in inhibiting apoptosis (92) and RSV NS2 was reported to 
enhance induction of NF-kB (104). Although some effects of the NS proteins appear to 
involve synergy between NS1 and NS2, this did not appear to be the case in the present 
study. Here, the cell morphologic and shedding phenotype attributed to RSV NS2 appeared 
to be independent of, and unaffected by, NS1. While the precise mechanism of NS2-
induced morphologic consequences remains unknown, we speculate that these events are 
not directly related to the ability of NS2 to modify interferon responses.   
Destruction of apical cilia structures and shedding of infected cells following RSV 
infection resulted in a net decline in the epithelial surface area with active cilia. Coordinated 
cilia beat is required for effective transport of particles across the airway surface and, as 
expected, a marked decline in mucociliary transport (MCT) rate was observed following RSV 
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infection. Interestingly, MCT rate began to decline prior to loss of ciliated epithelium, where, 
at day 4 pi, although ~60% of the epithelium displayed active cilia, MCT rate was drastically 
reduced. We therefore suggest that two processes modulated the RSV-mediated decline in 
MCT rate. First, RSV infection of an individual ciliated cell leads to degradation of the cilia 
apparatus before the infected cell is extruded from the epithelium. Ciliary dyskinesia and 
asynchronous cilia beat of infected cells disrupt unidirectional flow, resulting in local 
decreases in mucociliary transport. Second, as infection spreads, increased numbers of 
cells experience ciliary dyskinesia and the process of cell shedding removes ciliated cells 
from the epithelium. As fewer uninfected ciliated cells are available to provide for cilia beat, 
noted by a decrease in percentage of ciliated epithelium, MCT is abolished and RSV-
infected HAE are unable to transport shed cells across the airway epithelium. These factors 
are also likely to impair mucociliary clearance in vivo. 
 Unusual epithelial cell morphology and sloughing of virus antigen positive cells has 
been described for RSV-infected humans and bovine RSV-infected calves (116, 119, 161). 
The loss of cilia and disorganization of cilia basal bodies was reported in a bovine model of 
RSV infection, as we have noted in human ciliated cells infected by RSV and PIV3-NS2 
(116).  Ciliary dyskinesia and damage have also been reported in RSV-infected primary 
human ciliated cultures (175). Thus, in in vivo models of RSV infection and retrospective 
analysis of RSV-infected human lung tissue, shedding of virus infected epithelial cells and 
degradation of the cilia apparatus appear to be a characteristic of RSV infection.  
The mechanism by which RSV NS2 exerts its effects on epithelial cell rounding and 
shedding remains to be explored. Comparison of PIV3-NS2 infection of epithelial cell-line 
monolayers with PIV3 or PIV3-NS1 did not reveal a morphological phenotype specific to 
RSV NS2 (data not shown), suggesting the differentiated state of the columnar airway 
epithelial cells is a critical component of RSV N2-induced cell rounding. The use of 
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differentiated airway models such as HAE will therefore be critical in understanding how 
RSV NS2 modifies airway epithelial cells, resulting in shedding of infected cells into the 
airway lumen.  
The innate inflammatory response plays a critical role in RSV disease and 
recruitment of leukocytes to regions of infection occurs following secretion of 
chemoattractants, including IL-8, CXCL10, and RANTES. These cytokines are detected at 
elevated levels in nasophyngeal secretion and bronchoalveolar aspirates of infants 
experiencing RSV-associated bronchiolitis (143, 181). Elevated IL-8 levels in nasal washes 
are associated with more severe disease (144) and neutrophils, recruited by IL-8, are the 
major type of leukocyte detected in the airway of RSV-infected infants (180). Although these 
cytokines are secreted by a number of cell types, upreglation of IL-8, CXCL10, and 
RANTES gene expression in HAE following RSV infection suggests that ciliated cells play 
an important role in the recruitment of leukocytes. Interestingly, PIV3-NS2 infection of HAE 
results in more robust upregulation of IL-8 gene expression compared to PIV3 at 18 hours 
pi, suggesting a role for RSV NS2 in upregulation of IL-8. IL-1β secretion in nasophryngeal 
washes has also been positively correlated with RSV disease severity (133). In HAE, IL-1β 
gene transcription is elevated only a single timepoint, 4 days pi, suggesting other cell types, 
such as macrophages, may responsible for this increase. However, because we determined 
gene transcription, rather than protein secretion, cleavage of endogenous IL-1β precursor 
and secretion of mature IL-1β from the epithelium may occur in the absence of gene signal 
changes. In infected HAE, proinflammatory cytokine secretion may occur from infected cells 
as a direct result of viral replication or following paracrine activation of uninfected 
surrounding cells. These message studies do not differentiate between gene transcription in 
infected versus uninfected cells and we therefore cannot unequivocally determine the 
infection status and cell type responsible for driving cytokine secretion following RSV 
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infection. Regardless, these findings provide addition evidence for the central role of airway 
epithelial cells in modulating the inflammatory response following RSV infection. 
 In summary, we present evidence that infection of ciliated cells in a model of the 
human airway epithelium by RSV, but not by several other common respiratory 
paramyxoviruses, results in cell rounding, disruption of the cilia apparatus, active shedding 
of individual infected cells, and delay of apoptosis until infected cells are shed from the 
epithelium. We also demonstrate that infection of HAE results in increased gene 
transcription of proinflammatory cytokines associated with severe RSV-associated 
bronchiolitis. Thus, the consequences of RSV infection of HAE reflect several important 
characteristic hallmarks of RSV disease in infants. By performing loss-of-function and gain-
of-function experiments, we attribute these consequences of infection to the RSV NS2 
protein. We suggest that the NS2 protein is an important pathogenesis factor for RSV 
disease and may represent a therapeutic target to dampen disease severity. 
 
3.5 Materials and Methods 
Cells 
Human airway epithelial cells were isolated by the UNC Cystic Fibrosis Center Cell 
Culture and Tissue Procurement Core from tracheobronchial airway specimens obtained 
from patients provided by the National Disease Research Interchange (NDRI, Philadelphia, 
PA) or as excess tissue following lung transplantation. All protocols were approved by the 
University of North Carolina at Chapel Hill Institutional Review Board. Primary epithelial cells 
derived from single patient sources were plated on permeable Transwell-Col supports (12-
mm diameter, Corning, Inc.) and grown in custom media at an air-liquid interface for 8 to 10 
weeks to form differentiated, polarized cultures as previously described (211). HEp2 cells 
(ATCC) were maintain in MEM (Gibco) supplemented with 10% fetal bovine serum. LLC-
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MK2 cells (ATCC) were maintained in DMEM (Gibco) supplemented with 10% fetal bovine 
serum. 
Viruses  
All viruses used in this study were derived from cDNA (recombinant) and contain a 
GFP insertion as an additional gene unless otherwise stated.  
Recombinant human metapneumovirus (HMPV; strain CAN97-83), parainfluenza 
virus 5 (PIV5; strain W3A), and Sendai virus (SeV) were described previously (214, 220, 
221) and were provided by Drs. Peter Collins, Robert Lamb, and Daniel Kolakofsky, 
respectively. RSV Memphis 37 strain was isolated from a pediatric case of bronchiolitis and 
has been described previously (178). This virus is a primary low-passage clinical isolate, not 
a recombinant virus, and does not express GFP. This virus was provided by Dr. John 
DeVincenzo. 
Wild-type RSV, RSVΔNS1, RSVΔNS2, and RSVΔNS1/2 are derivatives of the A2 
strain and were constructed and described previously (105, 106, 212, 213). These viruses 
were provided by Dr. Peter Collins. Each of these RSV constructs express the green 
fluorescent protein (GFP) gene as an additional gene inserted between the RSV 
phosphoprotein (P) and matrix (M) genes. Wild-type RSV and all mutants were amplified in 
HEp2 cells stably expressing the V gene from SV5 (210). 
RSV viruses containing deletions of the NS2 gene are derivatives of the A2 strain 
and were constructed and provided by Michael Teng. An HA tag has been added to the N-
terminus of the NS2 gene in each of these constructs. These viruses were amplified in HEp2 
cells and do not contain a GFP gene insertion. 
PIV3 is a derivative of the JS strain engineered to express the GFP gene as an 
additional gene inserted between the PIV3 phosphoprotein (P) and matrix (M) genes, as has 
been described previously (81, 222). Codon-optimized RSV NS1 or NS2 genes were 
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synthesized (DNA2.0) and inserted into the PIV3 viral genome between the hemagglutinin-
neuraminidase (HN) and viral polymerase (L) genes using cloning methods similar to those 
previously used to express CFTR and rhAFP in this genome region (223, 224). A unique 
EagI restriction site was generated in the non-coding region downstream of the HN gene in 
the PIV3 subgenomic cDNA. The NS1 or NS2 coding sequence was amplified by RT-PCR 
from plasmids expressing codon-optimized NS1 or NS2 , cloned into a pCR-Blunt II-TOPO 
vector (Invitrogen), and sequenced. The following primer sets were used: NS1 sense (5’-
CCGCGGCCACCATGGGCAGCAATAGTCTC-3’), NS1 antisense (5’-
GGGCCCGAGTTATGGGTTCAGGTCAA-3’), NS2 sense (5’-
CCGCGGCCACAATGGATACCACGC-3’), and NS2 antisense (5’-
GGGCCCCTCGAGTCAAGGGTTCAA-3’). The underlined portions represent SacII and ApaI 
restriction sites. Using the SacII and ApaI restriction sites, NS1 or NS2 was inserted into a 
vector following a linker sequence consisting of the PIV3 gene-end, intergenic, and gene-
start transcription regions, flanked at both ends by EagI sites. This cassette was then 
inserted using the EagI sites into the full-length PIV3GFP antigenomic cDNA and the 
resulting genomes were designated PIV3-NS1 or PIV3-NS2. A PIV3 genome expressing 
both NS1 and NS2 was also generated by inserting the RSV NS1 and NS2 genes together 
into PIV3 between the HN and L genes using similar methods. From the linker vector 
containing NS1, a sequence consisting of the EagI restriction site, PIV3 linker region, and 
NS1 gene was PCR amplified using the NS1 sense primer (5’-
CGAATTGGCGGCCGAAAATA-3’) and the NS1 antisense primer (5’-
CAGGAGTTCAGCACGATGGGGGCCCGAGTTATGGGT-3’), destroying the 3’ EagI site 
and creating an 18bp overhang. From the linker vector containing NS2, a sequence 
consisting of the PIV3 linker region, the NS2 gene, and the EagI restriction site was 
amplified using the NS2 sense primer (5’-
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GCTGAACTCCTGCATCGTAAAATAAGAAAAACTTAG-3’)  and the NS2 antisense primer 
(5’-ACTTGGCCCAAGCTTGAGTA-3’), destroying the 5’ EagI site and adding the 
complementary 18bp overhang. These 2 fragments were combined in a fusion reaction 
using the NS1 sense and NS2 antisense primers and the resulting fragment was cloned into 
a pCRBluntII TOPO vector (Invitrogen) and sequenced. The final fragment consisted of a 
PIV3 linker region, the RSV NS1 gene, a second PIV3 linker region, and the RSV NS2 
gene, flanked by EagI sites. This cassette was then inserted using the EagI sites into the 
full-length PIV3GFP antigenomic cDNA, creating PIV3-NS1/2. Each insert was designed to 
retain the “rule of six” required for PIV3 genome replication. All viruses were rescued and 
amplified in LLC-MK2 cells using methods described previously (222) and sequenced.  
Viral inoculations and growth 
The apical surfaces of HAE were rinsed with PBS to remove excess airway 
secretions. Virus inoculum diluted in serum-free DMEM (Gibco; 100 µl per 12 mm well) was 
applied to the apical surface of HAE for 2 hrs at 37°C then removed by aspiration and the 
apical surfaces rinsed with PBS, and cultures incubated at 37°C. Viral growth kinetics were 
determined by performing apical surface washes with 300 µl of serum-free DMEM which 
were harvested after 30 min at 37oC and stored at −80°C until analysis. RSV viral titers in 
the apical washes were determined on HEp2 cells by titration and counting GFP-positive 
cells 24 h post-inoculation. PIV3 viral titers were determined by a 50% tissue culture 
infectious dose (TCID50) assay on LLC-MK2 cell monolayers, with positive wells scored by 
GFP expression. En face fluorescent images of GFP-positive cells in HAE were captured 
using a Leica DMIRB Inverted Fluorescent Microscope equipped with a Retiga 1300 CCD 
camera (Q-Imaging). The proportion of the surface area of epithelium positive for GFP was 
determined by pixilating a black-and-white image and calculating the percentage of black 
pixels using ImageJ software (NIH) for five fields per culture and averaging the results. 
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Histology and immunoprotocols  
Tight junctions were visualized by fixing HAE in 4% paraformaldehyde in PBS 
followed by permeabilization with 1.5% Triton-X100 in PBS. Immunodetection of ZO-1 was 
performed by blocking cultures in 3% bovine serum albumin (BSA) in PBS followed by 
incubation with a primary antibody against ZO-1 (mouse monoclonal, Invitrogen). 
Immunoreactivity was detected using an anti-mouse secondary conjugated to Alexafluor 594 
(Molecular Probes). En face images were captured on a Leica SP5 confocal microscope.  
For histological analysis, HAE fixed in 4% paraformaldehyde in PBS were paraffin 
embedded and 5 µm thick histological sections prepared. Sections were stained with 
hematoxylin and eosin (H&E) or Richardson’s stain. Immunodetection of RSV antigen and 
β-tubulin IV was performed by blocking sections in 3% bovine serum albumin (BSA) in PBS 
followed by incubation with primary antibodies against GFP (rabbit polyclonal; Abcam) and 
β-tubulin IV (mouse monoclonal; Sigma).  Immunoreactivity was detected using an anti-
rabbit IgG conjugated to Alexafluor 488 and an anti-mouse IgG conjugated to Alexafluor 594 
(Molecular Probes). In cases when we wished to preserve and visualize apical secretions of 
HAE, cultures were fixed in the alcohol-based fixative Omnifix (FR Chemical) as previously 
described (225) and stained with H&E. Immunohistochemistry for viral antigen were 
performed by blocking sections in 3% BSA and incubation with primary antibodies against 
RSV (anti-RSV goat polyclonal; Meridian Life Sciences) or PIV3 (anti-PIV3 rabbit serum 
raised against sucrose-gradient-purified PIV3; (226)). Immunoreactivity was detected using 
anti-goat or anti-rabbit secondary antibodies conjugated to horseradish peroxidase (HRP), 
visualized using 3,3’-diaminobenzidine (Sigma), and counterstained with hematoxylin. For 
transmission electron microscopy studies, HAE were fixed in glutaraldehyde solution 
followed by an osmium tetroxide solution to preserve the hydrated external environment of 
the HAE, as previously described (225), and visualized using standard TEM techniques. 
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Morphometric analysis of cell height and airway occlusion 
XZ confocal images were acquired using a Leica SP5 confocal microscope. XZ 
images through the tallest region of a GFP-positive infected cell in fixed but unprocessed 
HAE cultures were imported into ImageJ software (NIH) where pixel height was measured 
and converted to microns using the electronic magnification measurement bar from the 
confocal image. A minimum of 100 infected cells were measured from at least 3 individual 
donors. 
qRT-PCR 
 Cytokine gene expression at the mRNA level was determined by quantitative reverse 
transcription PCR (qRT-PCR). HAE were harvested at time points indicated and stored in 
RNAzol at −80°C until analysis. Total intracellular RNA was isolated from HAE samples 
using the RNeasy RNA Isolation kit (Qiagen). Complimentary DNA was generated using 
Oligo(dT) primers and SuperScript II reverse transcriptase (Invitrogen). Real-time PCR was 
performed using Taqman gene expression assays and an Applied Biosystems 7500 Fast 
Real-Time PCR System (Applied Biosystems). Input cDNA was normalized to GAPDH and 
signals were expressed as a ratio to mock-infected HAE signals.  
Cell shedding 
Cell shedding was quantified by determining the amount of double-stranded DNA 
(dsDNA) in apical washes of HAE using the Quant-It PicoGreen dsDNA kit (Invitrogen). 
Apical washes were performed with 300 μl serum-free DMEM for 30 min at 37°C. Washes 
were harvested and stored at −80°C prior to analysis. Samples were diluted five-fold in Tris-
EDTA buffer and dsDNA was measured in duplicate following manufacturer’s instructions 
using a 96-well plate format. dsDNA concentration per sample was calculated based on 
fluorescence of a titrated dsDNA standard. 
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Percentage area ciliated  
Following removal of apical washes for titer and cell shedding assays, HAE were 
allowed to come to room temperature for 15 min to normalize cilia beat frequency and 100 μl 
PBS was added apically. HAE were placed on an inverted phase contrast microscope 
(TE2000; Nikon) using a 20x objective and high speed (125Hz) video images were captured 
with an eight-bit b/w camera (GS-310 Turbo; Megaplus). The analog signal was digitized via 
an analog-to-digital converter board (A/D; National Instruments). A digital computerized 
analysis system was used to analyze the acquired video images, using software based on 
Sisson-Ammons Video Analysis (227).   
Mucociliary transport rates 
Following removal of apical washed for titer and shedding assays, green fluorescent 
microspheres (0.02% v/v, 1μm; Invitrogen) were added to the apical surface and HAE were 
incubated at 37oC. Time-lapse fluorescent images were obtained for 3 s using a Leica 
DMIRB Inverted Fluorescent Microscope equipped with a Retiga 1300 CCD camera (Q-
Imaging). The rate of microsphere displacement was calculated as previously described 
(223).  
Statistical analysis 
Unpaired t-test and one-way analysis of variance (ANOVA) with Tukey’s post-test 
was performed as indicated. Statistical significance was defined as P<0.05 unless otherwise 
noted. 
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Figure 3.1. RSV-GFP infection, replication, and clearance in HAE cultures. (A) 
Representative en face fluorescent images of GFP-positive cells in HAE infected with RSV 
expressing GFP at 1 (i), 3 (ii), 5 (iii), and 7 (iv) days post-inoculation. Scale bar represents 
200 µm. (B) Representative en face images of uninfected (i) or RSV infected (ii) HAE at 1d 
pi. Infected cells are detected by GFP fluorescence (green) and tight junctions are detected 
using an antibody against ZO-1 (red). Scale bar represents 10 µm. (C) The number of RSV 
infected cells in HAE over time quantified as the percentage of the epithelium surface area 
positive for GFP fluorescence. (D) Virus titers present in the airway surface fluid over time. 
Data (mean ± SEM) are representative of independent experiments utilizing at least n = 4 
cultures per donor obtained from 3 different donors.  
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Figure 3.2. IFN and cytokine production in HAE following infection with RSV-GFP. 
Expression levels of IFNβ (A), IL-1β (B), IL-8 (C), CXCL10 (D), RANTES (E), and TNFα (F) 
were determined in RSV and UV-inactivated RSV infected HAE. Total RNA was extracted 
from infected HAE at 12h pi and days 1, 2, 4, and 5 pi and gene expression levels were 
measured by qRT-PCR. Each sample was internally normalized to GAPDH and is 
expressed as fold change compared to mock-inoculated culture. Data (mean ± SD) 
represent n=3 cultures. Significant changes in mRNA levels of RSV relative to UV-
inactivated RSV were determined for each time point by unpaired t test. Unmarked: not 
significant; *P<0.05, **P<0.01, ***P < 0.001.  
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Figure 3.3. Morphologic and structural changes in RSV-infected ciliated columnar 
cells.  (A) Representative histologic sections of HAE inoculated with RSV expressing GFP 
and counterstained with H&E (i-iii) or immunoprobed for GFP (green) and beta-tubulin IV 
(red) (iv-vi) at 1 (i, iv), 3 (ii, v), and 5 (iii, vi) days pi. Yellow outlines in (Ai) depict the different 
ciliated cell morphologies seen in RSV infected HAE, where non-infected ciliated cells are 
columnar and RSV infected ciliated cells exhibit rounded morphology.  Arrowheads indicate 
robust apical terminal web in non-infected ciliated cells (i) which thins in RSV-infected 
ciliated cells with rounded morphology (iii). Images are representative of independent 
experiments with 4 different donor cultures. Scale bar represents 10 µm. (B) Representative 
transmission electron micrographs of cross-sections of the apical surfaces of non-infected (i) 
and RSV-GFP-infected (ii, iii) HAE. Arrowhead indicates particulates showing virus-like 
morphology. Star indicates disorganized basal bodies. Scale bar represents 1 µm. 
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Figure 3.4. Ciliated cell shedding and loss of cilia activity during RSV-GFP infection of 
HAE. (A) Representative images of histological cross-sections of non-infected (i) or HAE 
infected with RSV expressing GFP (ii) fixed at 5 days pi using a fixation protocol to preserve 
the content and depth of airway surface secretions. Scale bar represents 20 µm. (B) 
Concentration of dsDNA as an index for numbers of shed cells present in apical washes 
harvested every 24 h from non-infected (open circles) or RSV-infected (closed squares) 
HAE. Data (mean ± SEM) are derived from n = 4 cultures per donor for 4 different donors. 
(C) Fluorescent bead velocity as an index of mucus transport rates on the apical surfaces of 
non-infected (open circles) or RSV-infected (closed squares) HAE at indicated times post-
inoculation. Data (mean ± SEM) represent n = 3-6 cultures per donor for 3 different donors. 
(D) Surface area of active cilia beat on non-infected (open circles) or RSV-infected (closed 
squares) HAE. Data (mean ± SEM) represent n = 4. Data in panels (B) – (D) show 
significant differences at 3d pi (P<0.05) and at all time-points thereafter (P<0.001), as 
determined by unpaired t test.  
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Figure 3.5. RSV-induced ciliated cell rounding is unique to RSV infection and due to 
expression of the RSV NS2 protein. (A) Representative images of histologic cross-
sections of fixed and paraffin embedded HAE infected with recombinant RSV-GFP (i), low 
passage clinical isolate RSV Memphis 37 (ii), or recombinant PIV3-GFP (iii). Infected cells 
were detected at 3 days pi using an anti-RSV antibody (i, ii) or anti-PIV3 antibody (iii). Scale 
bar represents 10 µm. Height of infected ciliated cells (mean ± SD) was determined by 
confocal microscopy of fixed but unprocessed HAE infected with RSV, PIV3, human 
metapneumovirus (HMPV), parainfluenza virus 5 (PIV5), or Sendai virus (SeV) (iv). All 
viruses express GFP. At least 100 infected cells in cultures obtained from 3 different donors 
were measured. (B) Representative images of histologic cross-sections of HAE infected with 
RSV (i), or gene deletion mutants RSVΔNS1 (ii) and RSVΔNS2 (iii). All viruses express 
GFP. Height of infected cells (mean ± SD) was determined as in (Aiv). *P<0.05, **P<0.01, 
***P < 0.001, one-way ANOVA with Tukey’s post-test. 
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Figure 3.6. RSV-induced cell rounding is ablated by mutations within the NS2 protein. 
(A) Representative images of histologic cross sections of HAE infected with RSV or 
RSVΔNS2. (B) Schematic of sequential deletions of the NS2 protein. The NS2 ORF of RSV 
rA2 strain was replaced by a codon-optimized NS2 ORF with an N-terminal HA tag. 
Deletions were synthesized into the NS2 ORF, cloned into the RSV antigenome (A2 strain), 
and virus was rescued as previously described (105). Virus nomenclature indicates amino 
acid deletions in NS2 relative to the indicated C- or N-terminus. All viruses were amplified in 
HEp2 cells. (C) Representative images of histologic cross sections of HAE infected with the 
indicated RSV mutant virus.  Infected cells were detected at 3 days pi using an antibody 
against RSV. Equal levels of NS2, N, P, and M proteins were detectable by western blot of 
lysates from HEp2 cells infected with each virus (not shown). 
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Figure 3.7. Expression of RSV NS2 in HAE ciliated cells using PIV3 results in infected 
cell rounding. (A) Growth kinetics of recombinant PIV3 (open circles) and PIV3 expressing 
either RSV NS1 (PIV3-NS1, closed squares), NS2 (PIV3-NS2, open triangles) or both NS1 
and NS2 (PIV3-NS1/2, closed triangles). All viruses express GFP. Virus titers in apical 
washes were assessed at 24 h intervals. Data (mean ± SEM) represent n = 4 cultures per 
donor with cultures from 3 different donors. (B) Representative images of histologic cross-
sections of HAE infected with PIV3 (i), PIV3-NS1 (ii), PIV3-NS2 (iii), or PIV3-NS1/2 (iv). 
Infected cells were detected with an anti-PIV3 antibody. Scale bar indicates 10 µm. (C) 
Height of infected cells (mean ± SD) was determined as described in Figure 4. *P<0.05, 
**P<0.01, one-way ANOVA with Tukey’s post-test. 
80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
Figure  3.8. Expression of RSV NS2 by PIV3 in HAE cultures mimics RSV-induced 
cytopathology at the apical surface of ciliated cells. (A) Representative images of 
histologic sections of non-infected HAE (i), or HAE fixed 2d post-inoculation by RSV (ii), 
PIV3 (iii), PIV3-NS1 (iv), PIV3-NS2 (v), or PIV3-NS1/2 (vi) showing similar apical membrane 
disruption in ciliated cells infected by RSV, PIV3-NS2, and PIV3-NS1/2. Richardson’s 
counter stain. Scale bar represents 10 µm. (B) Surface area of active cilia beat on non-
infected (closed circles, dotted line), PIV3 (open circles), PIV3-NS1 (closed squares), PIV3-
NS2 (open triangles), or PIV3-NS1/2 (closed triangles) infected HAE. Data (mean ± SEM) 
represent quadruplicate cultures. All viruses express GFP. 
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Figure 3.9. IFN and cytokine changes following infection of HAE with PIV3, PIV3-NS1, 
or PIV3-NS2. HAE were mock inoculated or infected with PIV3, PIV3-NS1, or PIV3-NS2. At 
18 hours pi, cultures were harvested and message levels were determined by qRT-PCR for 
PIV3 N (A), IFN-β (B), IL-8 (C), and CXCL10 (D). Each sample was internally normalized to 
GAPDH and are expressed as fold change over mock inoculated culture. Data (mean ± SD) 
represent n=4 cultures. ns: not significant, *P<0.05, ***P<0.001, one way ANOVA with 
Tukey’s post-test. 
  
 
CHAPTER IV 
RSV NS2 PROTEIN PROMOTES EPITHELIAL CELL SHEDDING  
AND DISTAL AIRWAY OBSTRUCTION 
4.1 Overview 
Respiratory syncytial virus (RSV) infection is the major cause of bronchiolitis in 
young children. The factors contributing to an increased propensity of RSV-induced distal 
airway disease compared to other commonly encountered respiratory viruses remain 
unclear. Here, we identify the RSV non-structural 2 (NS2) protein as a unique viral genetic 
determinant for initiating RSV-induced distal airway obstruction. Using recombinant 
respiratory viruses and the hamster in vivo model of infection, we show RSV NS2 promotes 
shedding of infected cells, resulting in two effects. First, epithelial cell shedding accelerated 
clearance of virus titers, presumably by clearing virus-infected cells from airway mucosa. 
Second, epithelial cell shedding resulted in accumulation of detached, pleomorphic epithelial 
cells in the narrow diameter bronchiolar airway lumen, resulting in acute distal airway 
obstruction.  We propose that this study reveals a novel consequence of RSV infection of 
the airway epithelium, where NS2-promoted epithelial cell shedding accelerates viral 
clearance but also causes acute distal airway obstruction, possibly serving as the initiating 
event for bronchiolitis. Our studies identify a mechanism that may explain why RSV is the 
dominant virus causing bronchiolitis in young children and identify RSV NS2 as a novel 
therapeutic target for reducing the severity of disease.  
 
___________________________ 
Sections of this chapter are under review for publication in the Journal of Clinical Investigation. 
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4.2 Introduction 
Human respiratory syncytial virus (RSV) is a nonsegmented, negative-sense, single-
stranded RNA virus belonging to the family Paramyxoviridae, subfamily Pneumovirinae. 
RSV is the most common virus causing acute and severe lower airway disease in infants 
and young children, with nearly all children experiencing at least one RSV infection by the 
age of 2 years (1). While most RSV infections present with mild to moderate self-limiting 
pulmonary symptoms, in ~2% of cases, especially in infants who are very young (< 3 
months), premature, or who have underlying immunodeficiency or cardiopulmonary disease, 
lower airway disease is severe enough to require hospitalization (5). Worldwide, an 
estimated 34 million new pediatric cases of RSV-associated lower airway disease occur 
annually accounting for approximately 200,000 deaths, almost all occurring in developing 
countries with reduced access to standardized care (4).  
Despite significant impact of RSV infection on infant morbidity and mortality, 
treatment options remain limited to supportive care, poorly efficacious pharmacologic 
agents, and passively administered neutralizing antibodies. Supportive care including 
supplemental oxygen and ultimately, mechanical ventilation, remains the best available 
therapeutic approach. Ribavirin is the only anti-viral drug currently approved for treating 
RSV infections, but issues of efficacy, delivery, and potential side-effects in neonates restrict 
its use to immunocompromised patients (54). Bronchodilators and anti-inflammatory steroids 
are widely used to dampen inflammatory consequences of RSV infection despite evidence 
these treatments provide little to no clinical benefit (56, 57, 60). Passively administered 
neutralizing antibodies against RSV are used prophylactically to reduce the severity of RSV-
induced pulmonary disease in susceptible populations (47). However, these antibody 
treatments rely on expensive monthly injections and therefore are restricted to at-risk infants 
(228). Licensed RSV vaccines are currently unavailable, although actively under 
development. The high incidence of RSV infection and the potential for severe distal airway 
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disease in vulnerable young children combined with limited availability of therapeutic options 
identifies a significant clinical global need to reduce the burden of RSV infection and disease 
in infants and young children. 
RSV infects the mucosal epithelium lining the human respiratory tract, predominantly 
targeting the columnar epithelial cells of the conducting airways. The columnar airway 
epithelium serves a critical role in maintaining lung sterility by providing a physical barrier to 
systemic penetration of pathogens and generating and secreting antimicrobials. Additionally, 
the airway epithelium regulates mucus content, viscosity, and hydration to facilitate 
mechanical clearance of inhaled pathogens. Air-trapping and increased airway resistance 
are hallmarks of severe RSV-associated disease in the infant, although the factors 
contributing to these symptoms are unclear. Histologic analyses of lung tissues obtained 
post-mortem from RSV-infected infants describe epithelial cells positive for RSV antigen 
sloughed into the lumens of the infected airways (117, 119, 161). It was speculated that 
these intralumenal accumulations of infected and necrotic epithelial cells could contribute to 
airway obstruction and inflammation, exacerbating airway disease. Whether sloughing of 
airway epithelial cells was a direct consequence of RSV-induced epithelial cell 
cytopathology or a bystander effect of the robust infiltration and activation of inflammatory 
cells into the infected airways has been difficult to decipher in the complex in vivo 
environment of the lung. 
We have previously described an in vitro model of RSV infection of human 
cartilaginous airway epithelium (HAE) that recapitulates the cellular distribution and 
physiology of the human differentiated airway epithelium. Using this model, we and others 
have shown that RSV infects and spreads in HAE by preferentially infecting ciliated 
epithelial cells while sparing mucin-containing Goblet cells and the underlying basal 
epithelial cells (114, 115). These in vitro findings are supported by histologic studies of 
cartilaginous airways from RSV-infected patients that also demonstrate the preferential 
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tropism of RSV for ciliated cells (117). Tropism for ciliated cells is not unique to RSV, as 
other RNA viruses including paramyxoviruses, coronaviruses, and avian influenza viruses 
have been shown to preferentially infect ciliated cells in the HAE model (125, 229, 230).   
Previous studies have sought to determine the fate of RSV-infected ciliated cells 
over time in an in vitro primary differentiated model of the human airway epithelium. We 
demonstrated that infection of ciliated cells with RSV results in rounding of the infected cell, 
a unique consequence we attributed to expression of the RSV NS2 protein. Following a 
transition from a columnar to a rounded cell morphology, RSV infection of ciliated cells 
resulted in destruction of the cilia apparatus, loss of cilia function, and extrusion of the 
infected cell from the airway epithelium into lumenal secretions of HAE. Gain of function 
experiment using recombinant parainfluenza virus (PIV3-GFP) engineered to express RSV 
NS2 protein (PIV3-NS2) demonstrated that ciliated cells infected by PIV3-NS2, but not PIV3, 
became rounded and morphologically indistinguishable from RSV-infected ciliated cells. 
We now expand our in vitro studies to explore potential in vivo functions of RSV NS2 
expression. In this study, we compared the consequences of infection in the airways of 
Golden Syrian hamsters and show that PIV3-NS2, but not PIV3, caused rapid shedding of 
infected epithelial cells from the airway epithelium and accelerated clearance of virus 
infection from the lung. However, these studies also revealed PIV3-NS2 induced shedding 
of infected cells into the narrower diameter bronchiolar airways resulted in acute obstruction 
of the small airway lumens. Further, PIV3-NS2 infection causes earlier and more robust 
neutrophil influx in the lower airways of infected animals. These findings suggest the acute, 
distal airway obstruction, a common feature of RSV infection in infants, may be due to the 
rapid shedding of bronchiolar epithelial cells into the airway lumen and that this event is a 
direct consequence of RSV NS2 expression. These studies provide the first description of 
the unique fate of RSV-infected columnar airway epithelial cells and identify the expression 
of a single RSV protein, RSV NS2, as promoting this event.  
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4.3 Results 
Effects of PIV3-NS2 on the infection of the hamster nasal cavity and lower airways 
To determine the effects of RSV NS proteins in vivo, we used PIV3 as a vector to 
express NS1 and NS2. Among the convenient experimental animal models available, mice 
are not useful for PIV3 because of very poor virus replication in the airway epithelium, 
whereas Golden Syrian hamsters are semi-permissive to PIV3 infection and provide a useful 
model for infection. For these studies, we first focused on the airway epithelium of the 
hamster nasal cavity, as the nasal respiratory epithelium is a pseudostratified columnar 
epithelium with densities of ciliated and mucin-containing (Goblet) cells similar to those of 
HAE cultures and human cartilaginous airway epithelium in vivo. Hamsters were inoculated 
intranasally with PIV3, PIV3-NS2, or PIV3-NS1 (106 PFU). Maximal virus titers were reached 
in the nasal tissue by 3 days pi and revealed PIV3-NS1 and PIV3-NS2 were equally, but 
modestly, attenuated for growth compared to PIV3 (Figure 4.1A), similar to attenuation in 
HAE.  
We next identified virus-infected epithelial cells in histologic sections of hamster 
nasal epithelium by immunodetection of PIV3 antigen at the time point of maximal nasal 
titers, day 3 pi (Figure 4.1B). As predicted by our HAE studies, all recombinant PIV3 viruses 
infected ciliated cells but not mucin-containing Goblet cells of the hamster nasal respiratory 
epithelium. While ciliated cells infected by PIV3 or PIV3-NS1 retained the native columnar 
cell morphology, cells infected by PIV3-NS2 were rounded and resembled human ciliated 
cells infected by PIV3-NS2 or RSV in vitro. Morphometric analysis of infected ciliated cell 
height in histologic sections of hamster nasal respiratory epithelium revealed a significant 
shortening of ciliated cell infected by PIV3-NS2 compared to those infected by PIV3 or PIV3-
NS1 (Figure 4.1C), a phenotype remarkably similar to that seen in human cells in vitro.  
Occasionally in PIV3-NS2 infected hamster nasal cavities, virus antigen-positive cells were 
seen extruding from the epithelium and into the airway lumen but, unlike in HAE studies, 
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accumulations of shed, virus-infected epithelial cells after PIV3-NS2 infection were rarely 
noted in the nasal cavity, suggesting epithelial cells shed from the epithelium were rapidly 
and effectively cleared from the nasal cavity airway lumen, presumably by mechanical 
clearance mechanisms.  
Next, we explored the effects of RSV NS2 on PIV3 infection of the lungs of hamsters 
by comparing the consequences of infection with PIV3 or PIV3-NS2. Because PIV3-NS1-
infected cells showed no morphologic differences in HAE cultures or hamster nasal 
epithelium when compared to PIV3, we focused lung studies solely on the comparison of 
PIV3 versus PIV3-NS2 infection of hamster lower airways. For PIV3, histologic analysis of 
whole lungs after 3 days of infection showed viral antigen distributed throughout the 
conducting airways, predominately in the epithelial cells of the large bronchial and small 
bronchiolar airway regions (Figure 4.2Ai and 4.2Bi, respectively). Although virus antigen was 
occasionally detected in cells of the alveolar regions, the majority of infected cells were 
epithelial cells of the conducting airways. PIV3-infected epithelial cells of large and small 
airways retained columnar morphology and remained embedded in the epithelium, similar to 
PIV3-infected epithelial cells in HAE cultures. 
In contrast, in PIV3-NS2 inoculated hamsters at 3 days pi, all virus antigen-positive 
cells detected in the larger diameter airways were rounded and either shedding from or fully 
detached from the underlying intact epithelium (Figure 4.2Aiii). The smaller-diameter 
bronchiolar airways similarly showed extensive cell rounding and detachment (Figure 
4.2Biii). Remarkably, the narrow lumens of the bronchioles contained large accumulations of 
shed, virus antigen-positive cells (Figure 4.2Biii). This revealed an intriguing and 
unpredicted consequence of PIV3-NS2 infection. However, by 5 days pi, almost all evidence 
of infection and small airway occlusion was gone, suggesting effective clearance of the cell 
accumulations from the airway lumens (Figure 4.2Biv). The rapid clearance of virus-infected 
cells from within the bronchiolar airway lumen was also noted in the bronchial airways at 5 
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days pi (Figure 4.2Aiv). In contrast, the robust infection of the bronchial and bronchiolar 
airway epithelium in hamsters infected by PIV3 at 3 days pi was largely unaltered by 5 days 
pi, indicating PIV3-infected cells were not cleared as effectively from the epithelium as PIV3-
NS2 infected cells (Figure 4.2Aii and 4.2Bii).  
To determine if more effective clearance of virus-infected cells following PIV3-NS2 
infection influenced viral load in the lung, we harvested hamster lung tissues inoculated with 
PIV3-NS2 or PIV3 at 1, 2, 3, 5, and 7 days pi and measured whole lung virus titers. These 
data revealed a strong temporal correlation between the extent of virus antigen-positive cells 
and lung viral titers. Specifically, although the lung titers of PIV3 and PIV3-NS2 were very 
similar at 1 and 2 days pi, PIV3 titers declined by less than 1-log between 3 and 5 days pi, 
whereas the reduction in PIV3-NS2 titers was markedly accelerated, dropping almost 3-logs 
during the same 2-day period (Figure 4.3A).  Both viruses were completely cleared by 7 
days pi. Throughout the experiments, the hamsters showed no clinical signs of illness, as 
reported in previous studies of PIV3 infection of hamster airways (231). This is not surprising 
given the semi-permissive nature of PIV3 infection in this non-native host. To determine if 
infection impacted activity of hamsters, we measured the distance hamsters ran in a 24h 
period over 6 days of infection. Despite robust infection, neither PIV3 nor PIV3-NS2 infected 
hamsters ran significantly shorter distances as compared to control animals (Figure 4.3B).  
Neutrophil dominated inflammation in PIV3 and PIV3-NS2 infected animals 
We next characterized the inflammatory cell profile in both PIV3 and PIV3-NS2 
infected animals. Because these studies aim to determine early effects of infection on the 
ciliated airway epithelium, we focused only on immune cell infiltrates at 3 days pi. Cuffing of 
airways resulting from inflammatory cell infiltration into the parenchyma surrounding infected 
airways was evident in PIV3-NS2 infected animals, though such severe cuffing was rarely 
noted in PIV3 infected animals (Figure 4.4A). To determine the cell types present in the 
airway lumen, we performed bronchoalveolar lavage (BAL) on mock, PIV3, and PIV3-NS2 
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infected animals at 3 days pi. Consistent with observed increases in cellularity of PIV3-NS2 
infected airway lumens, BAL fluid from PIV3-NS2 infected animals contained roughly twice 
as many cells as mock or PIV3 infected animals (Figure 4.4 B). The cell types in BAL fluid 
were determined by morphological criteria and significantly elevated numbers of 
macrophages and neutrophils were retrieved from PIV3-NS2 infected animals as compared 
to mock or PIV3-infected animals (Figure 4.4C). Activated neutrophils release numerous 
effector proteins that contribute to neutrophil-mediated cytoxicity and, in proteomic analysis 
of cell-free BAL fluid, we detected elevated levels of neutrophil effector proteins. Neutrophil 
elastase was not detected in either mock or PIV3-infected animals but was present in PIV3-
NS2 infected animals (Figure 4.4D). Myeloperoxidase (MPO) was detected in low amounts 
in mock and PIV3 infected animals and, although not statistically significant, increased MPO 
was detected in BAL fluid of PIV3-NS2 infected animals (Figure 4.4E). Interestingly, 
histological analysis of the location of neutrophils in PIV3 or PIV3-NS2 infected animals 
indicated that, while in PIV3-infected animals neutrophils were associated with the airway 
epithelium, neutrophils in PIV3-NS2 infected animals were most frequently noted below the 
basement membrane or within the airway lumen (Figure 4.4F, arrow heads). 
Accumulation of shed cells in the distal airway of PIV3-NS2 infected hamsters 
In contrast to HAE and hamster nasal epithelium studies in which PIV3 only infected 
ciliated cells, we noted that PIV3 and PIV3-NS2 infected both ciliated and non-ciliated 
columnar cells of the small conducting airway regions. We also noted that PIV3-NS2-
infected cells shed into the small airways exhibited an unusual pleomorphic morphology 
compared to cells shed from HAE or the hamster nasal respiratory epithelium. PIV3-NS2-
infected cells shedding from small airway epithelium were swollen and at times bi-nucleated, 
with cell bodies extending from the intact epithelium into the airway lumen (Figure 4.5iv). 
Using cytokeratin 18 as an immunomarker for epithelial cells, we confirmed that the infected, 
shedding, and accumulated cells were epithelial cells, as expected (Figure 4.5Avi). The 
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accumulation of these detached, virus antigen-positive cells in the bronchioles infected by 
PIV3-NS2 was dramatic and sufficient to cause partial to complete occlusion of the 
bronchiolar lumens (Figure 4.5C). 
To determine the viability of shed cells, we stained airway sections for DNA 
fragmentation using TUNEL. In PIV3 infected airways, no TUNEL signal was noted in the 
airway, associated with the epithelium, or in the surrounding parenchyma. In contrast, 
TUNEL positivity was noted in the lumen and surrounding parenchyma of PIV3-NS2 infected 
airways, although the relative numbers of TUNEL positive cells were low. The majority of 
infected cells within the airway lumen were TUNEL negative, consistent with histological 
observation that the nuclei of shed cells in the airway lumen were morphologically intact. 
While we did not identify the cell type displaying TUNEL positivity, the location of staining 
suggests a combination of neutrophils and epithelial cells account for the TUNEL-positive 
cells of these airways. Additionally, we detected keratin 19 and 8, two major keratin 
components of the cytoskeletal scaffold of epithelial cells, in proteomic analysis of cell-free 
BAL fluid from PIV3 and PIV3-NS2 infected hamsters (Figure 4.5D, E). No keratins were 
detected in mock-inoculated animals. Although both keratins were detected in PIV3 animals, 
comparison of keratins detected in PIV3 versus PIV3-NS2 revealed a 3-fold increase in 
keratin 8 and an 8-fold increase in keratin 19 in BAL fluid from PIV3-NS2 infected animals. 
Analysis was undertaken on cell-free samples, thus the keratins detected in BAL fluid were 
likely released following necrosis of epithelial cells within the airway lumen. Consistent with 
this, necrotic debris was noted in histological sections of airway accumulations in the distal 
airways of PIV3-NS2 infected animals. 
Accumulation of infected cells in the distal airways of RSV infected infants 
To ascertain whether the morphologic consequences of PIV3-NS2 infection of 
hamster lower airways were predictive of events in lower airways of humans infected by 
RSV, we probed histologic sections of autopsy lung tissues obtained from RSV-infected 
92 
 
patients for viral antigen. Assessment of pseudostratified columnar airway epithelium, 
indicative of larger airway regions, showed clear evidence of RSV antigen-positive epithelial 
cells embedded in the epithelium, displaying shortened, rounded cell morphology (data not 
shown). Occasionally, RSV antigen-positive cells were also detected detached in the airway 
lumen, suggestive of shed, virus-infected cells which had not fully cleared from the airway. 
Examination of the distal bronchiolar airways revealed bronchiolar lumens partially or fully 
occluded by pleomorphic epithelial cells positive for RSV antigen and in some cases in the 
process of shedding into the airway lumen (Figure 4.6).  Swollen and bi-nucleated cells were 
also observed in the airway lumen of these regions. These observations indicated that the 
morphologic changes, cell shedding, and small airway occlusions observed in hamster distal 
airways infected by PIV3-NS2 resembled the consequences of RSV infection of human 
lower airways detected in post-mortem samples. 
 
4.4 Discussion 
RSV is the most important viral agent of lower airway disease in infants and young 
children and is commonly associated with severe bronchiolitis in these populations. In the 
very young, bronchiolitis caused by RSV is documented to be more severe and prolonged 
than bronchiolitis caused by other etiologies, including parainfluenza viruses (PIV) or 
rhinoviruses (9, 10). A recent study of young children with acute respiratory illness found 
those infected with RSV had twice as many emergency room visits and six times more 
hospitalizations than those with seasonal influenza virus infections (15). Why RSV has a 
tendency towards increased frequency and severity of distal small airway disease in infants 
amongst other etiologies was unknown.  
In vitro and in vivo studies have established that ciliated cells of the human large 
cartilaginous airways are an important target for RSV infection. The ciliated airway 
epithelium serves an important role in maintaining lung health, as it provides a mechanical 
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barrier against inhaled pathogens and contributes to clearance by facilitating mucociliary 
transport. Precisely how RSV infection of the airway epithelium causes disease was poorly 
defined, but it has previously been attributed to both direct virus-mediated epithelial cell 
cytopathology and exaggerated host immune responses, especially excessive neutrophil-
associated inflammation (181). Other consequences of RSV infection, such as incidence of 
wheezing and possible skewing of future immune responses, have been reported (34, 36). 
Although clinical and preclinical studies have increased our understanding of factors 
involved in RSV disease, the early, initiating aspects of RSV infection of the airway 
epithelium and the relationship to subsequent airway pathology remained poorly defined.  
Investigating the role of the airway epithelium in RSV pathogenesis has been 
impeded by the scarcity of representative models of polarized and differentiated airway 
epithelium that are both susceptible to human RSV infection and mimic the outcomes of 
infection observed in RSV-infected human airways in vivo. Indeed, most experiments 
modeling RSV infection of the airway epithelium rely on transformed epithelial cell-line 
monolayers, which do not resemble the differentiated architecture of airway epithelium in 
vivo. The widely available in vivo models, particularly small rodents, also poorly reproduce 
the consequences of RSV infection observed in human airways, largely due to low infectivity 
of the conducting airway epithelial cells. Species-specific RSV equivalents used in 
appropriate permissive hosts, such as bovine RSV in calves, are useful models for 
understanding RSV pathogenesis, but differences between the human and animal viruses 
and the human and animal hosts have been documented and complicate such analyses 
(209). 
In the previous chapter, we assessed the impact of RSV NS2 on the function of the 
airway epithelium using RSV gene-deletion mutants to infect cultures of primary human 
pseudostratified airway epithelial cells (HAE) that closely resemble the epithelium of 
authentic airway tissue. These studies demonstrated that cell rounding and shedding were 
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dependent on expression of the RSV NS2 protein. However, these gene-deletion mutants 
lacked the major RSV type I interferon antagonist proteins and are severely attenuated in 
HAE. Because PIV3 also targets ciliated cells but does not cause the cell rounding 
phenotype, we used PIV3 as a vector to express RSV genes in ciliated cells. Infection of 
ciliated cells in vitro with PIV3 engineered to express RSV NS2 (PIV3-NS2) resulted in 
infected cell morphologic changes indistinguishable from ciliated cells infected by RSV.  
In this present study, we used PIV3-NS2 and control viruses to investigate the 
significance of our in vitro HAE findings in an in vivo hamster model. Evaluation of infection 
by PIV3-NS2 and control viruses in the hamster nasal respiratory epithelium, which mimics 
HAE in its distribution of ciliated and non-ciliated Goblet cells, showed that PIV3 
recombinant viruses infected only ciliated cells in the respiratory epithelium and that PIV3-
NS2 caused the same cell rounding, membrane cytopathology, and shedding phenotypes 
associated with the expression of RSV NS2 in ciliated cells of HAE. 
Similar to outcomes in HAE and hamster nasal ciliated cells, infection of hamster 
lower airway epithelial cells with PIV3-NS2, but not PIV3, resulted in rounding and shedding 
of the infected cells from the epithelium into the airway lumen. In contrast, PIV3-infected 
epithelial cells remained columnar and embedded within the intact epithelium. In the large 
airways of hamsters infected with PIV3-NS2, infected cells that shed from the epithelium 
rarely accumulated in the airway lumen, suggesting that the majority of shed cells were 
rapidly and effectively cleared from the lumen, presumably by mechanical airway clearance 
mechanisms. In the narrower diameter small airways, shed cells accumulated in the airway 
lumen, suggesting clearance of shed cells from the small airway lumens was delayed. 
These effects were most pronounced in the small airways of hamsters 2-3 days after 
infection by PIV3-NS2, and accumulations of detached virus-antigen-positive cells were 
easily detected as occlusions in the small airway lumens, reminiscent of bronchiolar airway 
occlusions frequently observed in the small airways of young infants infected by RSV. We 
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also note studies with RSV-infected infants describe infection of the larger airways as 
patches or clusters of infected cells compared to more robust circumferential infection of 
distal airway epithelial cells (117, 118). Our in vivo studies with PIV3-NS2 suggest patchy 
infection in the large airways may represent continuous shedding and clearance of infected 
cells in these regions, while shedding and accumulation may perpetuate infection in the 
distal airways. 
Despite histological evidence of epithelial cells in the airway lumen, few epithelial 
cells were noted in lavage fluid of PIV3-NS2 infected hamsters. It is possible that occlusions 
containing epithelial cells are not easily flushed from the airways and were not collected 
using the lavage technique. Histological sections of lungs post-BAL showed some evidence 
of occlusions remaining in the airway. Alteranatively, morphologic changes of epithelial cells 
following infection with PIV3-NS2, especially cell swelling, may have resulted in some 
epithelial cells being misidentified and counted as macrophages, since cell types were 
determined by morphological characteristics. Immunodetection of specific cell type markers 
could be used to complement future analysis of the cell types present in BAL fluid. 
The narrower diameter of the small airway lumens likely is a significant factor in the 
development of airway occlusions. Similarly, narrow airway lumen size is suggested to 
contribute to the increased frequency of small airway obstruction associated with infants 
infected by RSV. However, we also noted that cells shedding into the hamster or human 
small airways exhibited an unusual swollen and pleomorphic morphology compared to cells 
shedding from HAE, the hamster nasal respiratory epithelium, or the hamster larger airways. 
These airway region-dependent consequences of PIV3-NS2 infection may reflect a 
difference in the responses of ciliated cells distributed in the small airways compared to 
those in the large airways. Alternatively, the swollen pleomorphic cells may represent other 
epithelial cell-types present in the small airways which are susceptible to PIV3-NS2 
infection, such as the non-ciliated columnar club (Clara) cell. In human and hamster lower 
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airways, club cell numbers increase in density as the conducting airways descend into the 
distal bronchiolar airway regions (113, 232). Indeed, in our studies in hamster airways, we 
noted PIV3 and PIV3-NS2 infection of both ciliated and non-ciliated columnar epithelial cells 
of the distal airways, the latter likely representing club cells. RSV infects both ciliated and 
non-ciliated cells in the small airways of humans (117, 119) and both cell types are infected 
in the small airways of calves and lambs experimentally infected with RSV (116, 149). Thus, 
the apparent morphologic differences in the cells shed into the smaller compared to larger 
airways might reflect the increased frequency of PIV3-NS2 infection of club cells in the small 
airways versus infection of ciliated cells in the larger airways. Regardless of the specific 
epithelial cell-types infected by PIV3-NS2 in the different airway regions, we suggest that the 
combination of narrower diameter airway lumens in the bronchioles and the expanded 
volume of cells shed into these airway regions enhances the likelihood that shed cells would 
accumulate and occlude the smaller diameter airway lumens. 
 Unusual epithelial cell morphology has been described for RSV-infected humans and 
bovine RSV-infected calves (116, 119, 161) and sloughing of virus antigen-positive cells 
caused small airways occlusion in ovine and baboon models of RSV infection (149, 153). In 
contrast, unusual airway epithelial cell morphologies are rarely noted after RSV inoculation 
of small animal models, most notably the mouse. Thus, in several appropriate large animal 
models of RSV infection as well as retrospective analysis of human cases of RSV infection, 
shedding of pleomorphic, virus antigen-positive epithelial cells, especially in the smaller 
diameter distal airways, appears to be a characteristic hallmark of RSV infection.  
 The appearance of cell accumulations and airway lumen occlusions in the small 
airways of hamsters infected with PIV3-NS2 suggests that the phenomenon of RSV NS2-
induced cell shedding might have importance for RSV disease. RSV bronchiolitis has long 
been associated with small airway obstruction resulting in air-trapping distal to the 
obstruction, leading to increased airway resistance (233, 234). Classically, the composition 
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of the obstructive material has been considered to be a mixture of necrotic epithelial cells, 
mucus secretions, and inflammatory cell exudate. However, the limited number of autopsy 
specimens now available from RSV-infected patients, including those described in this 
study, reveal unusual pleomorphic epithelial cells shedding from the airway epithelium and 
RSV antigen-positive debris accumulating in the lumen of infected airways, with only rare 
examples of mucus-related airway plugging, further emphasizing the potential significance 
of shed and accumulated epithelial cells as a major contributor to small airway obstruction 
after RSV infection.   
 The present study suggests that RSV, compared to other common respiratory 
paramyxoviruses, has an unusual ability to induce epithelial cell shedding, and that NS2-
induced cell shedding may be an important factor in RSV pathogenesis by contributing to 
plugging of small airway lumens. However, in the hamster model, the small airway plugging 
observed in association with PIV3-NS2 infection was transient, as maximal occlusion 
occurred at 3 days pi but was cleared by 5 days pi. Obstruction of small airways was also 
not associated with increased clinical disease in hamsters. The lack of disease associated 
with PIV3 (and RSV) infection in rodent models largely reflects their semi-permissive nature 
for virus replication, with relatively low whole lung viral titers and relatively short durations of 
infection. In contrast, RSV infection of humans results in substantially higher virus titers and 
virus shedding can continue for one or several weeks (178, 235). Primary RSV infection in 
humans is nearly always symptomatic and, in this more permissive setting, it is reasonable 
to expect that RSV NS2-promoted occlusion of the small airways would be longer-lived and 
contribute to disease severity. It also is likely that RSV-induced cytopathology leading to 
inhibition of mucociliary activity would have a greater effect on mechanical clearance in a 
more permissive setting, due to longer duration and increased extent of infection, which 
would further reduce clearance of shed cells. 
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 Interestingly, we also noted an additional effect associated with NS2-induced cell 
shedding.  Specifically, PIV3-NS2 infection was cleared from hamster lungs more rapidly 
than PIV3. This was evident by histologic analysis, which showed that, despite the extensive 
infection and airway occlusions associated with PIV3-NS2 on day 3, the infected cells were 
largely cleared by day 5. In contrast, in animals infected with PIV3, there were abundant 
infected cells on both days 3 and 5 pi. Consistent with this, quantification of whole lung viral 
titers confirmed that PIV3-NS2 was cleared more rapidly than PIV3, even though both 
viruses reached similar peak titers by days 2-3. These data raise the possibility that the cell 
shedding promoted by RSV NS2 might have a potential beneficial effect for the host, namely 
to accelerate clearance of virus-infected cells and infection from the airways. This 
observation, however, is based on indirect evidence, specifically the impact of RSV NS2 on 
the clearance of PIV3 rather than RSV. 
Neutrophils are the primary immune cell type notes in bronchial washes of RSV 
infected infants (180). Similarly, we noted a large influx of neutrophils at 3 days pi in PIV3-
NS2 infected hamsters. At this timepoint, inflammation was minimal around PIV3 infected 
airways, though present at later timepoints (5 days pi) in these animals. In agreement with 
histological findings, increased numbers of neutrophils and macrophages were also noted in 
BAL fluid collected from hamsters infected with PIV3-NS2 at 3 days pi and the neutrophil 
effector proteins MPO and neutrophil elastase were present in cell-free BAL fluid. While 
neutrophils were present in and around the airways of both PIV3 and PIV3-NS2 infected 
airways, albeit at differing levels, histologic examination suggests differential location of 
neutophils in the distal airway regions of infected animals. Specifically, neutrophils in PIV3 
infected airways appeared to be directly associated with the lumenal surface of the airway 
epithelium. In contrast, neutrophils in PIV3-NS2 infected airways were frequently noted 
either below the basement membrane, having not yet migrated across the airway 
epithelium, or within the airway lumen not in contact with the intact airway epithelium. The 
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presence of neutrophils in the airway lumen, rather than directly associated with the 
epithelium suggests that neutrophils are associating with the infected, shed cells in PIV3-
NS2 infected animals rather than cells within the airway epithelium. Differences in neutrophil 
location may reflect a protective response of the host, whereby neutrophils associate with 
shed cells rather than cells within the epithelium, protecting the epithelium from neutrophil-
mediated cytotoxicity. Alternatively, cell shedding may represent an immune evasion 
mechanism of the virus, where removal of the infected cells from the epithelium might 
decrease the likelihood that infected cells will directly encounter inflammatory cells recruited 
to site of infection.  
 At this time, it is not possible to assess the relative importance of the seemingly 
contrasting effects demonstrated in this study, namely shedding resulting in clogged airways 
and potentially enhanced disease versus shedding resulting in accelerated clearance and 
reduced disease. Unfortunately, it is not feasible to evaluate obstruction versus clearance of 
RSV using NS gene deletion mutants because, as noted, deletion of these proteins has 
drastic effects on host antiviral responses and causes severe attenuation of the mutants in 
vivo, which would confound this analysis. However, the central role of airway plugging in 
RSV pathogenesis in humans suggests that NS2-induced cell shedding and morphological 
changes are important to the development RSV disease in vivo.  
 In summary, using PIV3 as a vector for RSV NS2, we confirm the previous in vitro 
finding that NS2 mediated cell rounding in an in vivo hamster model of infection. We then 
expand on the previous in vitro studies by demonstrating that expression of RSV NS2 in vivo 
resulted in accelerated clearance of infection. We propose that NS2-induced cell shedding 
acts as a novel clearance mechanism to remove infected cells from both the airway 
epithelium and the lumen. In the narrow diameter distal airways, however, NS2-induced 
shedding contributed to acute airway obstruction which was strikingly reminiscent of airway 
plugging that occurs during RSV bronchiolitis in infants. The notion that RSV NS2 may be a 
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pathogenesis factor increasing the likelihood of small airway obstruction as a precursor to 
bronchiolitis identifies NS2 as a potential therapeutic target for limiting the severity and 
frequency of RSV bronchiolitis, particularly in infants. It also suggests that deletion of the 
NS2 gene may be desirable in live-attenuated RSV vaccine candidates (69). Future studies 
will be needed to explore how RSV NS2-mediated shedding of infected cells affects the 
development of immunity to RSV infection and whether manipulation of NS2-promoted 
epithelial cell shedding in response to RSV infection may serve as a therapeutic target for 
reducing the severity of distal airway disease in RSV-infected infants.    
 
4.5 Materials and Methods 
Animals 
In vivo animal studies used Golden Syrian hamsters (Harlan) and all procedures 
were conducted in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals and using animal study protocols approved by the Animal Care 
and Use Committee of the National Institute of Allergy and Infectious Diseases and the 
Institutional Animal Care and Use Committee of the University of North Carolina at Chapel 
Hill.  
Viruses  
All viruses used in this study were derived from cDNA (recombinant) and contain a 
GFP insertion as an additional gene unless otherwise mentioned.  
Wild-type RSV is a derivative of the A2 strain and was constructed and described 
previously (212). This virus expresses the green fluorescent protein (GFP) gene as an 
additional gene inserted between the RSV phosphoprotein (P) and matrix (M) genes. Wild-
type RSV and all mutants were amplified in HEp2 cells stably expressing the V gene from 
SV5 (210). 
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PIV3 is a derivative of the JS strain engineered to express the GFP gene as an 
additional gene inserted between the PIV3 phosphoprotein (P) and matrix (M) genes, as has 
been described previously (81, 222). Codon-optimized RSV NS1 or NS2 genes were 
synthesized (DNA2.0) and inserted into the PIV3 viral genome between the hemagglutinin-
neuraminidase (HN) and viral polymerase (L) genes using cloning methods similar to those 
previously used to express CFTR and rhAFP in this genome region (223, 224). A unique 
EagI restriction site was generated in the non-coding region downstream of the HN gene in 
the PIV3 subgenomic cDNA. The NS1 or NS2 coding sequence was amplified by RT-PCR 
from plasmids expressing codon-optimized NS1 or NS2 , cloned into a pCR-Blunt II-TOPO 
vector (Invitrogen), and sequenced. The following primer sets were used: NS1 sense (5’-
CCGCGGCCACCATGGGCAGCAATAGTCTC-3’), NS1 antisense (5’-
GGGCCCGAGTTATGGGTTCAGGTCAA-3’), NS2 sense (5’-
CCGCGGCCACAATGGATACCACGC-3’), and NS2 antisense (5’-
GGGCCCCTCGAGTCAAGGGTTCAA-3’). The underlined portions represent SacII and ApaI 
restriction sites. Using the SacII and ApaI restriction sites, NS1 or NS2 was inserted into a 
vector following a linker sequence consisting of the PIV3 gene-end, intergenic, and gene-
start transcription regions, flanked at both ends by EagI sites. This cassette was then 
inserted using the EagI sites into the full-length PIV3GFP antigenomic cDNA and the 
resulting genomes were designated PIV3-NS1 or PIV3-NS2. A PIV3 genome expressing 
both NS1 and NS2 was also generated by inserting the RSV NS1 and NS2 genes together 
into PIV3 between the HN and L genes using similar methods. From the linker vector 
containing NS1, a sequence consisting of the EagI restriction site, PIV3 linker region, and 
NS1 gene was PCR amplified using the NS1 sense primer (5’-
CGAATTGGCGGCCGAAAATA-3’) and the NS1 antisense primer (5’-
CAGGAGTTCAGCACGATGGGGGCCCGAGTTATGGGT-3’), destroying the 3’ EagI site 
and creating an 18bp overhang. From the linker vector containing NS2, a sequence 
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consisting of the PIV3 linker region, the NS2 gene, and the EagI restriction site was 
amplified using the NS2 sense primer (5’-
GCTGAACTCCTGCATCGTAAAATAAGAAAAACTTAG-3’)  and the NS2 antisense primer 
(5’-ACTTGGCCCAAGCTTGAGTA-3’), destroying the 5’ EagI site and adding the 
complementary 18bp overhang. These 2 fragments were combined in a fusion reaction 
using the NS1 sense and NS2 antisense primers and the resulting fragment was cloned into 
a pCRBluntII TOPO vector (Invitrogen) and sequenced. The final fragment consisted of a 
PIV3 linker region, the RSV NS1 gene, a second PIV3 linker region, and the RSV NS2 
gene, flanked by EagI sites. This cassette was then inserted using the EagI sites into the 
full-length PIV3GFP antigenomic cDNA, creating PIV3-NS1/2. Each insert was designed to 
retain the “rule of six” required for PIV3 genome replication. All viruses were rescued and 
amplified in LLC-MK2 cells using methods described previously (222) and sequenced.  
Viral inoculations and growth 
Ten- to twelve-week-old female Golden Syrian hamsters (Harlan) were transiently 
anesthetized (methoxyflurane) and inoculated intranasally with 106 pfu of PIV3, PIV3-NS1, 
or PIV3-NS2 in 100 μl serum-free L-15 Leibovitz medium (Gibco).  Animals were euthanized 
and respiratory tissues harvested at indicated times post-inoculation for analysis of virus 
titers or histologic assessment.  For virus titrations, whole lungs or nasal turbinates were 
weighed and homogenized in PBS. Viral titers were determined by standard plaque assay of 
the clarified supernatants as previously described (236). 
Histology and immunoprotocols  
For histologic examination of hamster tissues, excised nasal turbinates or whole 
lungs were immersion-fixed in 10% neutral-buffered formalin, embedded in paraffin, and 
histological sections generated for examination and staining. Sections were stained with 
H&E. Immunohistochemistry for viral antigen was performed by blocking sections in 3% BSA 
and incubation with primary antibodies against PIV3 (anti-PIV3 rabbit serum raised against 
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sucrose-gradient-purified PIV3; (226)). To identify epithelial cells, a cytokeratin 18 antibody 
was used (mouse monoclonal; Abcam). Immunoreactivity was detected using anti-goat or 
anti-rabbit secondary antibodies conjugated to horseradish peroxidase (HRP), visualized 
using 3,3’-diaminobenzidine (Sigma), and counterstained with hematoxylin.  
RSV infection in human airways was determined in lung tissue obtained from a 
patient naturally infected by RSV provided by Dr. Alan Proia is association with the Duke 
University Pathology Specimen Repository in accordance with Duke University IRB 
protocols. RSV and cytokeratin 8/18 immunoreactivity was performed on histological 
sections using a Leica Bond-III automated stainers (Leica Microsystems Inc.).  Following 
antigen retrieval with Novocastra Bond Epitope Retrieval 1 solution (Leica Microsystems), 
sections were incubated with a primary antibody against RSV antigen (clones 5H5N, 2G12, 
5A6, IC3; Vector Laboratories) and detected with the Novocastra Bond Polymer Refine 
Detection system (Leica Microsystems). Immunostaining for CK 8/18 used a proteinase K 
epitope retrieval solution (Dako North America, Inc.), the primary antibody Novocastra CK 
8/18 monoclonal antibody (clone 5D3, Leica Microsystems), and detection with the 
Novocastra Bond Polymer Refine Detection system.   
Morphometric analysis of cell height and airway occlusion 
Height of infected cells in the nasal respiratory tissue was determined by measuring 
pixel height of infected cells in images from fixed, viral-antigen stained sections using 
ImageJ software (NIH) and converting to microns.  
Occlusion of airways was determined by imaging infected airway regions from fixed, 
viral-antigen stained sections, converting to black-and-white images, pixilating, and 
calculating the percentage of black pixels within the airway lumen using ImageJ software. 
Airway occlusions were measured from 3 individual animals harvested at 3days pi. 
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Bronchoalveolar lavage 
Bronchoalveolar lavages were performed using standardized procedures (237). 
Hamsters were euthanized by exsanguination under deep Avertin anesthesia. The left main 
stem bronchus was ligated to perform BAL on the right lobe only. Two ml cold sterile PBS 
was instilled and retrieved via the trachea three times before collection and cell counting.  
BAL cells were pelleted by centrifugation at 1000xg for 5min at 4°C and the cell-free fluid 
(BALF) was collected and stored at -80°C for future analysis. BAL cells were resuspended in 
PBS and cytospin slides of 30,000-60,000 cells/slide were obtained (StatSpin CytoFuge 2), 
air dried, and stained with Newcomer’s stain for differential cell counts.  
Proteomics of BALF 
 LC-MS/MS identification of proteins in cell-free BAL fluid (BALF) was performed as 
described previously (238). A total of 100 μl of BALF from each hamster was denatured with 
300 μl GuHCL (pH8.0) and proteins were reduced with 20mM dithiothreitol for 30m at 60oC 
and alkylated with iodoacetamide (Sigma) for 1h at 25oC. Reduced and alkylated BAL 
samples were buffer-exchanged into a pH 8.0 digestion buffer using a HiTrap Desalting 
column (GE Healthcare) and digested with 2 μg trypsin at 37oC overnight. The final digest 
was vacuum dried to remove bicarbonate salts and resolubilized in 20 μl 0.1% formic acid 
water.  
 The LC-MS/MS was performed with a Dionex ultimate 3000 RSLCnano system 
coupled to a hybid quadrupole orbitrap mass spectrometer with a Nano spray source (Q 
Exactive, Thermo Fisher).  For liquid chromatography, one microliter of the sample was 
loaded into a trap column Acclaim PepMap 2 cm × 75 μm i.d., C18, 3 μm, 100 A (Dionex) at 
5 µl/min with aqueous solution containing 0.05 % (v/v) trifluoroacetic acid and 2 % 
acetonitrile. After 7 minutes, the trap column was set on line with an analytical column 
Acclaim PepMap RSLC 15 cm × 75 μm i.d., C18, 2 μm, 100 A (Dionex) with a linear 
gradient of 4-30 % solvent B (99.9% acetonitrile with 0.1% formic acid) over 157 min with a 
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constant flow of 300 nL/min. Eluted Peptides were analyzed by a data-dependent top 10 
method dynamically choosing the most abundant precursor ions from the survey scan (300–
1650 Th) for HCD fragmentation. For MS scan, data were acquired at resolution of 70,000 at 
m/z 200, target AGC value of 1e6, maximum fill times of 80 ms. For the MS/MS scan, data 
were acquired at resolution of 17,500 at m/z 200, target AGC value of 1e5, maximum fill 
times of 80 ms. Dynamic exclusion was set to 20 second. 
Proteins identified from the BALF were quantified using a label-free method termed 
the normalized spectral index (SIN) (239). SIN is defined as the cumulative fragment ion 
intensities for all spectra counted for a protein (SI) normalized by the sum of SI over all 
proteins and by the length of the protein.  
Running wheels 
 To determine if infection results in decreased activity, a Nalgene activity wheel 
(Nalge Nunc International) was placed in each hamster cage, equipped with a magnetic 
switch with an LCD counter that records revolutions, with water and food available ad 
libitum. Running wheels were place in each cage for 2 days prior to inoculations for baseline 
recording of activity and to allow for exploration and acclimation. Following inoculation, 
activity was recorded as number of revolutions per 24 hour period and reported as distance 
run per day. 
Statistical analysis 
Unpaired t-test and one-way analysis of variance (ANOVA) with Tukey’s post-test 
was performed as indicated. Statistical significance was defined as P<0.05 unless otherwise 
noted. 
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Figure 4.1. PIV3-NS2 causes ciliated cell rounding in the hamster nasal respiratory 
epithelium in vivo. (A) The nasal epithelium of Golden Syrian hamsters was inoculated 
with 106 PFU of PIV3 (closed circles), PIV3-NS1 (open squares), or PIV3-NS2 (closed 
triangles) and virus titers in the nasal turbinates was determined at 3 days pi. Data (mean ± 
SEM) represent 3 independent experiments with total of 9 - 12 animals. (B) Representative 
images of histologic cross-sections of hamster nasal respiratory epithelium infected by PIV3 
(i), PIV3-NS1 (ii), or PIV3-NS2 (iii). Virus antigen was detected at 3 days pi with an anti-PIV3 
antibody. Scale bar represents 10 µm. (C) Height of infected ciliated cells (mean ± SD) was 
determined by measuring height of virus-antigen positive cells from fixed tissue sections with 
at least 200 cells analyzed across 3 individual animals. All viruses express GFP. ***P 
<0.001, one-way ANOVA with Tukey’s post test. 
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Figure 4.2. Accelerated clearance of virus-infected cells in hamsters infected by PIV3-
NS2. (A, B) Representative images of histologic cross-sections of hamster large airways (A) 
and small airways (B) 3 days (i, iii) and 5 days (ii, iv) after infection with PIV3 (i, ii) or PIV3-
NS2 (iii, iv). Note the rapid loss of PIV3-NS2 infected cells from airways at 5 days pi, a time 
when PIV3 infection remained robust.  Scale bar represents 100 µm.  
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Figure 4.3 Accelerated clearance of viral load in hamsters infected by PIV3-NS2. (A) 
Whole lung virus loads in hamsters infected with PIV3 (closed circles) or PIV3-NS2 (open 
squares) measured over time, demonstrating a more rapid clearance of PIV3 infection when 
the virus expresses RSV NS2.  Data (mean ± SEM) represent 3 independent experiments 
with total of 4 – 9 animals per timepoint. All viruses express GFP. ***P <0.0001, unpaired t 
test. (B) Daily running wheel distance in hamsters mock inoculated (closed triangles, dotted 
line) or inoculated with PIV3 (closed circles, solid line) or PIV3-NS2 (open squares, solid 
line). Despite differences in whole lung viral load and lower airway infection, no difference in 
running distance, an index of clinical disease, was evident. Data represent 2 – 3 animals per 
timepoint. 
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Figure 4.4. Neutrophilic inflammation in distal airways of PIV3-NS2 infected hamsters. 
(A) Representative images of H&E stained histologic cross-sections of the smaller airways 
in hamsters mock inoculated (i) or infected with PIV3 (ii) or PIV3-NS2 (iii) at 3 days pi. Scale 
bar represents 100 µm. (B) Total cell counts in bronchoalveolar lavage (BAL) fluid of 
infected hamsters at 3 days pi. (C) Cytospins of cells from BAL of mock-inoculated hamsters 
(black bar) or hamsters infected with PIV3 (dotted bar) or PIV3-NS2 (striped bar) were 
Giemsa stained and cell types (macrophages, neutrophils, eosinophils, lymphocytes, and 
epithelial cells) were differentiated by morphologic criteria and counted. (D, E) Identification 
and relative abundance of the neutrophil effector proteins neutrophil elastase (D) and 
myeloperoxidase (E) were determined in cell free BAL fluid at 3 days pi by LC-MS/MS based 
identification and label-free quantification using the normalized spectral index method (239). 
(F) Representative images of neutrophils in the lumen of PIV3-infected animals (i) at 5 days 
pi or PIV3-NS2 infected animals (ii) at 3 days pi, the respective times of peak neutrophil 
influx. Arrow heads denote examples of neutrophils. Scale bar represents 50 µm. All 
quantitative data (mean ± SEM) represent n = 4 animals. n.d. not detected *P<0.05, one-
way ANOVA with Tukey’s post-test. 
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Figure 4.5. Shedding of cells infected by PIV3-NS2 but not PIV3 into hamster lower 
conducting airways. (A) Representative images from histologic cross-sections of hamster 
distal airways infected with PIV3 (i - iii) and PIV3-NS2 (iv - vi). Sections were stained with 
H&E (i, iv), or with antibody against PIV3 to identify PIV3-infected cells (ii, v), or with an 
antibody against cytokeratin 18 to identify epithelial cells (iii, vi) at 3 days pi. Scale bar 
represents 50 µm. (B) Representative images from histologic cross-sections of hamster 
distal airways infected with PIV3 (i) and PIV3-NS2 (ii). Sections were stained for viral 
antigen (green) and nuclei (blue). Apoptotic cells were identified by TUNEL staining (red). 
Note the majority of infected cells in the airway lumen are negative for TUNEL staining. (C) 
Morphometric quantitative analysis of distal airway cell accumulation in hamsters infected 
with PIV3 or PIV3-NS2 by measuring the percentage of cross-sectional airway lumen 
surface area occupied by virus antigen-positive cells at 3 days pi. Histologic, antigen-stained 
whole lung sections from 3 animals were measured and each symbol represents occlusion 
of an individual airway. ***P <0.0001, unpaired t test. (D, E) Identification and relative 
abundance of the epithelial cell specific proteins keratin 19 (D) and keratin 8 (E) were 
determined in cell free bronchoalveolar lavage fluid (BALF) at 3 days pi by LC-MS/MS 
based identification and label-free quantification using the normalized spectral index method 
(239). Keratins in cell-free BALF likely originate from apoptotic or necrotic epithelial cells in 
the airway lumen. Data (mean ± SEM) represent n = 4 animals. n.d. not detected, **P<0.01, 
one-way ANOVA with Tukey’s post-test. 
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Figure 4.6. Shedding of cells infected by RSV into lower airways of human. 
Representative images of histologic cross-sections of human lower airways obtained post-
mortem from a patient naturally infected by RSV. Sections were stained with H&E (i), or with 
an RSV-specific antibody to detect infected cells (ii), or with a cytokeratin 8/18 antibody to 
detect epithelial cells (iii). Scale bar represents 50 µm. Note the smaller diameter distal 
airways of humans demonstrate virus antigen-positive cells shedding and accumulation in 
the lumen, often sufficient to cause airway occlusion, similar to accumulations noted in the 
hamster distal airways.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
CHAPTER V 
CONCLUSIONS 
Respiratory syncytial virus is a significant pathogen that targets the respiratory 
mucosa and, in infants, is the most frequent cause of severe lower respiratory tract illness, 
often presenting as bronchiolitis. The goal of this dissertation was to understand the 
interactions between RSV and the airway epithelium and to define the cytopathogenic 
effects of RSV on the primary target of infection, the ciliated cell. 
From the studies presented in this dissertation, we conclude the following: 
I. RSV infection of human ciliated cells is resolved in vitro by a ciliated cell shedding 
response. 
A. RSV targets columnar ciliated cells of the human airway epithelium and induces 
cytokine expression associated with severe RSV disease.   
RSV demonstrated tropism for ciliated cells in a primary, well-differentiated model of 
the pseudostratified human airway epithelium (HAE) and infection was not documented in 
any other cell type, including Goblet cells and basal cells. Efficient initial infection of HAE 
was dependent upon the presence of the mature form of the RSV glycoprotein protein G, 
emphasizing the requirement for G in attachment and entry. HAE cultures supported RSV 
replication and spread, though clearance of infected cells and viral titer was noted at later 
times after infection. Replication induced increases in gene transcription of common antiviral 
genes, including IFNβ, IL-1β, IL-8, CXCL10, RANTES, and TNF-α, in a time dependent 
manner.  
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RSV tropism for ciliated cells has been previously documented by our group and 
others (114, 115, 131) and ciliated cell tropism has also been demonstrated a number of 
additional respiratory viruses, including other myxoviruses (125, 230, 240, 241). As the 
primary target of RSV infection, ciliated cells are uniquely positioned to initiate and modulate 
the antiviral response of the airway epithelium. Initiation of antiviral gene transcription likely 
contributes to limitation of viral replication and recruitment of infiltrating immune cells in the 
context of in vivo infection.  
The innate inflammatory response plays a critical role in RSV disease and 
proinflammatory cytokines, such as IL-1β and TNF-α, and chemoattractants, such as IL-8, 
CXCL10, and RANTES, are elevated in nasophryngeal secretions and bronchoalveolar 
washes of infants with RSV-associated bronchiolitis (132, 136, 142, 143), with increased 
levels of IL-1β and IL-8 being independently associated with severe disease (118, 133, 144). 
We provide evidence that airway cells play a central role in modulating the inflammatory 
response by regulating these cytokines following RSV infection, though the relative 
contribution of in vivo cytokine secretion from the infected epithelia compared to other cell 
types such as airway macrophages is unclear. 
 Interestingly, our studies suggested a role for the RSV NS2 protein in upregulation of 
IL-8. Consistent with this, previous work has shown that infection of A549 cells with RSV 
deleted for the NS2 gene resulted in reduced secretion of IL-8 compared to wild-type virus 
or RSV deleted for the NS1 gene alone (104). The promotor region of the IL-8 gene contains 
binding site for p65 (242) and NS2 has been previously shown to play a role in p65 
translocation to the nucleus (92, 104), suggesting a possible mechanism for NS2-mediated 
IL-8 upregulation. Furthermore, IL-8 is a major chemoattractant for neutrophils, which are 
the most predominate type of leukocyte detected in the airways of RSV-infected infants 
(180). The notion that neutrophilic inflammation may be enhanced by NS2 identifies NS2 as 
a major pathogenesis factor contributing to disease severity. 
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B. RSV infection of ciliated cells results in destruction of the cilia apparatus, ciliated 
cells shedding, and impairment of mucociliary clearance.  
Previous studies of ciliated airway epithelial cultures have documented RSV-induced 
ciliary dyskinesia, a decline in the presence of cilia following RSV infection, and sloughing of 
cells from infected cultures (114, 124, 175). We confirm these features of RSV infection and 
expand on previous studies with several important findings. First, we attribute damage to the 
cilia and cilia structures following RSV infection to expression of the NS2 protein, further 
emphasizing the role of NS2 in RSV pathogenesis. Next, we demonstrate that clearance of 
viral infection in vitro is driven by active shedding of infected cells from the epithelium and 
that, based on histologic criteria, apoptosis of infected cells is delayed until complete 
extrusion of the cell from the epithelium into the apical compartment. Finally, we 
demonstrate that the combined effects of cilia degradation and infected cell shedding 
abolished the ability of the epithelium to perform mucociliary transport following RSV 
infection and these factors are likely to significantly impair mucociliary clearance in vivo.  
We speculate that delay of apoptosis until cells are fully detached from the 
epithelium is an important ciliated cell response that, in vivo, serves to dampen the 
inflammatory response and decrease potential damage to the barrier function of the airway 
epithelium. Apoptotic cells shed from the epithelium are subsequently available for 
phagocytosis or mechanical clearance. Viruses frequently evade or delay apoptosis to allow 
for enhanced replication and the RSV life-cycle likely benefits from delay of cell shedding 
and retention of the ciliated cell in the airway epithelium. The RSV NS1 and NS2 proteins 
delay apoptosis in tissue culture cells lines through activation of cellular anti-apoptotic NF-
kB and AKT pathways and these same pathways may be important for suppression of 
apoptosis in ciliated epithelial cells (92). Interestingly, infection of ciliated cells with PIV3 
expressing NS1 results in no visible effect on apical surface structures and minimal cell 
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shedding, despite robust infection, potentially identifying a more important role in the pro-
survival pathway for the NS1 protein as compared to NS2.  
Mucociliary clearance is a critical innate defense mechanism of the airway epithelium 
and coordinated cilia beat is of utmost importance to maintenance of the mucociliary 
escalator function of the human airway. Therefore, the cytopathogenic effects of RSV on 
cilia function and mucociliary clearance likely have profound clinical implications. Shedding 
of cells into the airway lumen combined with impaired mucociliary clearance may contribute 
to the accumulation of antigen-positive cells noted in the airway lumen of RSV infected 
animals and infants (116-118, 153). In the large airways, where patchy and noncontiguous 
infection is often noted, mucociliary clearance may be maintained by surrounding regions of 
airways with healthy epithelia, allowing for clearance of infected cell debris. However, in the 
smaller airways where ciliated cells are fewer in number and infection is often noted as 
circumferential (117), it is possible that RSV infection leads to greater loss of ciliated cells 
and a more significant decline in mucotransport ability that may result in accumulation of 
infected cells in the airway lumen. Intralumenal accumulations of cells and debris likely 
contribute to airway obstruction and inflammation, potentially exacerbating RSV disease.  
II. RSV-induced retraction of the ciliated cell tail is attributable to the RSV NS2 
protein. 
In the pseudostratified airway epithelium of the cartilaginous airway regions, ciliated 
cells are columnar in morphology, spanning the length of epithelium with the cilia on the 
apical surface extending into the airway lumen while the ciliated cell tail remains embedded 
within the underlying basal cell layer. Infection of ciliated columnar cells with RSV results in 
a transition from the native columnar morphology to a rounded morphology and this 
morphologic phenotype is unique to RSV, as no other viruses tested in our airway model 
underwent cell rounding as a result of infection. Because recent studies have identified 
phenotypic differences between highly passaged laboratory strains of RSV, such as the A2 
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strain used in these studies, and clinical isolates (243), we confirmed that the recently 
isolated clinical strain of RSV (Memphis 37) caused morphological changes in infected cells 
similar to cells infected with the recombinant GFP-expressing RSV. Cell rounding also 
occurred following infection of HAE with a recombinant RSV without GFP, the biological-
derived RSV from which the recombinant was generated, and a wild-type subgroup B RSV, 
identifying cell rounding as unique consequence specific to RSV infection of ciliated cells. 
Using gene deletion mutants, we attribute the rounding function to the RSV NS2 protein.  
Morphological changes in RSV infected cells have been frequently noted in animal 
models of RSV disease and histological examination of tissue from RSV-infected infants 
(116, 119, 153, 161, 244). Retrospective investigation of tissue sections from children with 
lower respiratory illness demonstrated RSV antigen-positive multi-nucleated epithelial cells 
and giant cell proliferation in the airway lumen (161). The earliest studies describe these 
lesions as a “bizarre derangement of the epithelium” and note a “mass of cytoplasm 
attached by a thread to the epithelial basement” (161). Similarly, in calves infected with 
bovine RSV, large irregular cytoplasmic projects and hyperplastic epithelial cells were 
described (116). We suggest that the rounding morphology of RSV infected ciliated cells in 
vitro, driven by expression of the NS2 protein, directly correlates to the abnormal 
morphological changes noted in previous studies of RSV infection in vivo. 
The mechanism of NS2-induced ciliated cell rounding is currently unclear. 
Comparison of cell monolayers infected with RSV, RSVΔNS2, PIV3, and PIV3-NS2 did not 
reveal a morphological phenotype specific to the NS2 protein (data not shown), suggesting 
the polarized and differentiated state of the ciliated airway epithelium is a critical component 
of RSV-mediated cell rounding. Cellular pathways known to modulate morphological 
features of polarized cells are future avenues of exploration and represent a potentially 
unidentified pathway of interaction with the RSV NS2 protein. Notably, RSV has been shown 
to modify actin filaments and keratin intermediate filaments during viral assembly and egress 
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(245-248). Cytoskeletal scaffolds comprised of keratin intermediate filaments (KIFs) are 
essential for the cell-cell adhesion and structural integrity of cells, and post-translational 
modification of KIFs, by phosphorylation or O-glycosylation, occurs in response to cellular 
stress. Cleavage and reorganization of keratin 18 (K18), a primary KIF of ciliated cells, 
occurs during apoptosis (249) and increased phosphorylation of K18 leads to keratin 
reorganization, differential localization, and changes in protein association (250-252). A role 
for NS2-mediated modification of keratin intermediate filaments to promote or enable 
epithelial cell shedding represents an intriguing hypothesis. 
III. Expression of RSV NS2 dramatically alters PIV3 infection kinetics in vivo. 
A. RSV NS2 enhances shedding of PIV3-infected cells into the airway lumen and 
accelerates mechanical airway clearance of infection in vivo. 
We next used the hamster model of paramyxovirus infection to evaluate the 
significance of in vitro findings related to the cytopathic effect of NS2 on ciliated cells. The 
hamster nasal respiratory epithelium is comprised of similar cell types as HAE and similar 
outcomes were observed in this region following infection with PIV3-NS2. Both PIV3 and 
PIV3-NS2 specifically target ciliated cells for infection and no viral antigen was noted in 
goblet or basal cells. As in HAE, PIV3-NS2 infection of ciliated cells resulted in rounding, 
cilia cytopathology, and shedding of infected cells, leaving the underlying epithelium intact. 
In contrast, PIV3-infected cells retained the native columnar morphology and remained 
embedded within the epithelium. Similarly, in the larger airways, PIV3-NS2 infection resulted 
in cell rounding and shedding, and viral antigen positive cells were most frequently located 
within the airway lumen. Over time, shed cells in large airways of PIV3-NS2 infected animals 
were likely cleared by mucociliary clearance mechanisms. PIV3 infected similar numbers of 
cells, although cells remained columnar and embedded in the epithelium, with viral-antigen 
positive cells or cellular debris rarely noted in the airway lumen. Additionally, we found that 
PIV3-NS2 was cleared from the hamster lungs more rapidly than PIV3. These data raise the 
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possibility that cell shedding may accelerate clearance of virus-infected cells and viral 
antigen from the airways, representing a protective cellular response triggered by the NS2 
protein. 
B. RSV NS2 enhanced shedding of infected cells in the small airways results in acute 
airway obstruction. 
 Although cell shedding may promote accelerated clearance in the large airways, 
shedding of infected cells into the narrower diameter distal airways resulted in accumulation 
of cells in the airway lumen. In many airways, sufficient cell accumulation resulted in partial 
to complete obstruction of the airway lumen and occlusions were composed primarily of 
intact antigen positive epithelial cells, with little contribution of necrotic debris and immune 
infiltrates. PIV3-NS2 infected cells in the small airways of hamsters displayed an unusual 
swollen and pleomorphic morphology, exaggerating the morphological changes noted in 
infected cells in HAE, the hamster nasal epithelium, and the hamster larger airways. 
Notably, distal airway obstruction associated with PIV3-NS2 was transient and was not 
associated with clinical signs of disease.  
We suggest that enlarged and pleomorphic infected cells in the distal airway may 
reveal cell-type specific differences in NS2-mediated morphological phenotype. These 
swollen pleomorphic cells may represent infection of another cell type present in the smaller 
airway regions, such as the non-ciliated club (Clara) cell. In the human and hamster airways, 
club cells increase in density as the conducting airways descend into the distal airway 
region (113, 232). Infection of both ciliated and non-ciliated epithelial cells was noted in the 
hamster distal airways, the latter likely representing club cells. Similarly, RSV infection of 
both ciliated and non-ciliated cells has been observed in the small airways of humans, 
calves, and lambs (116-119, 153). The apparent morphologic difference in shed cells within 
different regions of the airway may reflect the increased frequency of PIV3-NS2 infection of 
club cells in the smaller airway compared to ciliated cells in the larger airway. We suggest 
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that the combination of narrower diameter airway lumens and expanded volume of cells 
shed into these regions enhances the likelihood that shed cells would accumulate and 
occlude the smaller diameter airway lumens.  
Distal airway obstructions in PIV3-NS2 infected animals were strikingly reminiscent 
of bronchiolar airway occlusions observed in the small airways of infects with RSV-
associated bronchiolitis and we speculate that RSV NS2-induced cell shedding has 
important implications for RSV disease. RSV bronchiolitis has long been associated with 
small airway obstruction resulting in air-trapping distal to the regions of obstruction, leading 
to decreased pulmonary function and increased airway resistance. Tissue sections from 
RSV-infected patients and studies of large animal models of infection reveal accumulation of 
RSV antigen-positive debris in the lumen of infected airways, further emphasizing the 
potential significance of shed and accumulated epithelial cells as a major contributor to 
small airway obstruction after RSV infection. Furthermore, RSV-associated bronchiolitis is 
known to be more severe than bronchiolitis associated with other respiratory pathogens 
such as rhinovirus and parainfluenza viruses (9, 10).  Non-RSV bronchiolitis is characterized 
by pulmonary edema and inflammatory infiltrates, resulting in constriction of the bronchiolar 
airways. Additional bronchiolar involvement and occlusion due to accumulation of shed 
RSV-infected cells may account for the more severe consequences associated with RSV 
bronchiolitis.  
We speculate that epithelial cell shedding promoted by NS2 may also provide unique 
evolutionary benefits to the RSV life-cycle. Shedding of virus-infected cells may, for 
example, contribute to the spread of infection throughout the respiratory tract, such as by 
pulmonary aspiration of upper airway secretions laden with shed infected cells into the lower 
respiratory tract. Shed cells in the large and small airways appear viable and viral replication 
and shedding may continue as these cells are transported within the respiratory tract. It is 
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also possible that occlusion of airways may contribute to prolonging disease, thereby 
increasing the opportunity for viral transmission to secondary contacts.  
C. RSV NS2 exaggerates neutrophil recruitment to distal airways. 
In hamsters infected with PIV3-NS2, histological evidence indicated earlier and more 
robust neutrophil recruitment to infected airways, and both neutrophils and proteins secreted 
by neutrophils were elevated bronchoalveolar lavage fluid of PIV3-NS2 infected animals at 3 
days pi. Furthermore, analysis of inflammation in histological sections revealed an intriguing 
difference in the location of neutrophils in airways of PIV3 and PIV3-NS2 infected animals. 
PIV3 infection resulted in neutrophil recruitment into the airway lumen at later time points (5 
days pi), and neutrophils were frequently noted to be associated with the epithelium, 
presumably at locations of infection. In contrast, although PIV3-NS2 animals had larger 
numbers of inflammatory cells at earlier time points (3 days pi), neutrophils were often 
observed below the basement membrane, having not yet migrated across the airway 
epithelium, or within the airway lumen, not directly associated with the respiratory 
epithelium, suggesting that neutrophils are associating with the infected, shed cells in PIV3-
NS2 infected animals rather than the airway epithelium.  
Neutrophil infiltration is characteristic of RSV infection and neutrophils make up a 
high percentage of infiltrating leuokocytes in both human studies and animal models of 
infection (116, 180). Studies in mice suggested that neutrophils were recruited by CD8+ T 
lymphocytes (253), however more recent evidence indicated that neutrophil recruitment is 
mediated by cytokine release from the infected airway epithelium. In HAE, we found that 
airway epithelial cells upregulated IL-8 and CXCL10, major neutrophil recruitment cytokines, 
in response to RSV and PIV3-NS2 infection, suggesting that infected epithelial cells play a 
significant role in recruitment of neutrophils to site of infection.  
Neutrophil location may have several implications for RSV pathogenesis. RSV 
infected cells display the neutrophil adhesion protein ICAM-1 at the cell surface (191, 193, 
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194) and shedding of these infected cells may have a protective effect for the host, where 
neutrophils in the airway lumen adhere to shed cells, rather than cells within the airway 
epithelium. In this case, release of cytotoxic neutrophil effector proteins, such as elastase 
and MPO, in the lumen, rather than directly at the epithelium, may decrease damage to the 
epithelium and help maintain barrier integrity. Conversely, cell shedding may represent an 
immune evasion mechanism of the virus, where removal of the infected cell from the 
epithelium might decrease the likelihood that infected cells will directly encounter 
inflammatory cells recruited to site of infection. In this scenario, shedding of the infected cell 
into the airway lumen might reduce neutrophil migration across the respiratory epithelium, as 
neutrophils in the parenchyma can no longer interact with ICAM-1 on the infected cell to 
facilitate migration across the respiratory mucosa. Clearance of shed cells would further 
dampen recruitment signals to site of infection. Virus infected cells that remain in the 
epithelium, such as occurs in PIV3 infection, likely recruit inflammatory infiltrates and enable 
direct interactions between infiltrates and infected cells. In the context of RSV, cell shedding 
resulting in reduction of interactions between immune cells and virus-infected cells may 
significantly impact the development of immunity to RSV.  
Summary 
These studies present evidence for a critical role of ciliated cells in development of 
RSV disease. The observations reported in this dissertation provide new insight into the viral 
and cellular mechanisms of RSV infection of ciliated cells and define a novel role for the 
RSV NS2 protein in modulating key pathogenic changes in RSV-infected cells. Use of a 
well-differentiated model of the human airway allowed for identification of morphological 
consequence of RSV infection not present in cell line monolayers, namely transition of 
infected ciliated cells from the native columnar morphology to a rounded morphology. 
Further, we identify in vivo correlates of in vitro observations using recombinant viruses and 
the hamster model of infection. In the hamster, we identify two key outcomes of NS2-
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mediated morphological changes and cell shedding. In the larger airways, RSV NS2 
promotes enhanced clearance of viral infection mediated by clearance of virally infected, 
shed cells. In the smaller airways, RSV NS2 enhances acute airway obstruction due to 
narrower airway diameter and increased size of shed cells. Addtionally, we demonstrate 
early and robust neutrophil influx in the distal airway regions, mediated by the NS2 protein in 
the context of a viral infection. Acute airway obstruction is a key feature in severe RSV-
associated bronchiolitis and these studies identify the NS2 protein as the primary mediator 
of early airway obstruction. We suggest that NS2-mediated cell shedding and obstruction 
represent a critical initiating event that contributes to airway pathology associated with 
severe RSV-mediated bronchiolitis. 
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